https://trial.medpath.com/news/exactech-announces-fda-clearance-of-truliant-r-porous-3d-tibial-implant-for-knee 2024-10-31T16:37:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exactech-announces-fda-clearance-of-truliant-r-porous-3d-tibial-implant-for-knee 2024-10-31T16:37:37+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-weekly-support-for-commercialization-of-complex-therapies-regmednet 2024-10-31T16:37:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cell-therapy-weekly-support-for-commercialization-of-complex-therapies-regmednet 2024-10-31T16:37:08+00:00 weekly 0.7 https://trial.medpath.com/news/potentially-transformative-new-breast-cancer-drug-could-stop-disease-in-its-tracks-irish-star 2024-10-31T16:20:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/potentially-transformative-new-breast-cancer-drug-could-stop-disease-in-its-tracks-irish-star 2024-10-31T16:20:34+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-presents-latest-clinical-findings-suggesting-inhibition-of-tau-propagation-by-anti 2024-10-31T16:19:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-presents-latest-clinical-findings-suggesting-inhibition-of-tau-propagation-by-anti 2024-10-31T16:19:35+00:00 weekly 0.7 https://trial.medpath.com/news/vitamin-k2-reduces-dreaded-nighttime-leg-cramps-in-clinical-trial-medical-xpress 2024-10-31T16:14:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vitamin-k2-reduces-dreaded-nighttime-leg-cramps-in-clinical-trial-medical-xpress 2024-10-31T16:14:04+00:00 weekly 0.7 https://trial.medpath.com/news/court-upholds-fda-approval-of-avadel-s-narcolepsy-drug-lumryz-investing-com 2024-10-31T16:09:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/court-upholds-fda-approval-of-avadel-s-narcolepsy-drug-lumryz-investing-com 2024-10-31T16:09:42+00:00 weekly 0.7 https://trial.medpath.com/news/sacituzumab-tirumotecan-nda-for-pretreated-egfr-nsclc-accepted-for-review-in-china 2024-10-31T16:08:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sacituzumab-tirumotecan-nda-for-pretreated-egfr-nsclc-accepted-for-review-in-china 2024-10-31T16:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-nivolumab-in-high-risk-muscle-invasive-urothelial-carcinoma-the-asco-post 2024-10-31T16:05:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adjuvant-nivolumab-in-high-risk-muscle-invasive-urothelial-carcinoma-the-asco-post 2024-10-31T16:05:44+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-strategy-could-restore-delayed-onset-hearing-loss-drug-discovery-news 2024-10-31T16:04:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crispr-strategy-could-restore-delayed-onset-hearing-loss-drug-discovery-news 2024-10-31T16:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/hope-biosciences-research-foundation-reports-promising-phase-ii-trial-results-for-stem 2024-10-31T15:54:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-biosciences-research-foundation-reports-promising-phase-ii-trial-results-for-stem 2024-10-31T15:54:21+00:00 weekly 0.7 https://trial.medpath.com/news/powerful-new-therapy-doubles-progression-free-survival-in-advanced-breast-cancer-clinical-trial-finds 2024-10-31T15:44:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/powerful-new-therapy-doubles-progression-free-survival-in-advanced-breast-cancer-clinical-trial-finds 2024-10-31T15:44:52+00:00 weekly 0.7 https://trial.medpath.com/news/sinaptica-s-neuromodulation-device-aces-phase-ii-alzheimer-s-trial-clinical-trials-arena 2024-10-31T15:36:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sinaptica-s-neuromodulation-device-aces-phase-ii-alzheimer-s-trial-clinical-trials-arena 2024-10-31T15:36:13+00:00 weekly 0.7 https://trial.medpath.com/news/hope-biosciences-research-foundation-reports-promising-phase-ii-trial-results-for-stem 2024-10-31T15:36:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-biosciences-research-foundation-reports-promising-phase-ii-trial-results-for-stem 2024-10-31T15:36:11+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-cas13bt3-silences-vegfa-in-retinal-cells 2024-10-31T15:26:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crispr-cas13bt3-silences-vegfa-in-retinal-cells 2024-10-31T15:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-down-as-morgan-stanley-cuts-rating-on-sluggish-alzheimer-s-drug-launch 2024-10-31T15:23:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-down-as-morgan-stanley-cuts-rating-on-sluggish-alzheimer-s-drug-launch 2024-10-31T15:23:49+00:00 weekly 0.7 https://trial.medpath.com/news/evommune-raises-115m-to-accelerate-immune-drug-tests-biopharma-dive 2024-10-31T15:14:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evommune-raises-115m-to-accelerate-immune-drug-tests-biopharma-dive 2024-10-31T15:14:53+00:00 weekly 0.7 https://trial.medpath.com/news/ovarian-cancer-produces-il-4-to-resist-immunotherapy-inside-precision-medicine 2024-10-31T15:12:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ovarian-cancer-produces-il-4-to-resist-immunotherapy-inside-precision-medicine 2024-10-31T15:12:29+00:00 weekly 0.7 https://trial.medpath.com/news/nda-submitted-for-3-month-formulation-of-mesylate-for-advanced-prostate-cancer 2024-10-31T15:09:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nda-submitted-for-3-month-formulation-of-mesylate-for-advanced-prostate-cancer 2024-10-31T15:09:11+00:00 weekly 0.7 https://trial.medpath.com/news/nda-submitted-for-3-month-formulation-of-mesylate-for-advanced-prostate-cancer 2024-10-31T15:09:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nda-submitted-for-3-month-formulation-of-mesylate-for-advanced-prostate-cancer 2024-10-31T15:09:11+00:00 weekly 0.7 https://trial.medpath.com/news/tuberculosis-how-close-are-we-to-a-new-vaccine-the-bmj 2024-10-31T15:08:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tuberculosis-how-close-are-we-to-a-new-vaccine-the-bmj 2024-10-31T15:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/navigating-esr1-mutations-in-hr-positive-breast-cancer-with-dr-wander 2024-10-31T15:08:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/navigating-esr1-mutations-in-hr-positive-breast-cancer-with-dr-wander 2024-10-31T15:08:45+00:00 weekly 0.7 https://trial.medpath.com/news/compass-delays-pivotal-trial-readouts-for-psilocybin-in-depression-lays-off-30-of-staff 2024-10-31T15:05:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/compass-delays-pivotal-trial-readouts-for-psilocybin-in-depression-lays-off-30-of-staff 2024-10-31T15:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/genomic-screening-of-nyc-newborns-highlights-parent-s-interest-and-useful-findings 2024-10-31T14:53:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genomic-screening-of-nyc-newborns-highlights-parent-s-interest-and-useful-findings 2024-10-31T14:53:09+00:00 weekly 0.7 https://trial.medpath.com/news/paclitaxel-or-sirolimus-coated-balloons-used-for-arteriovenous-fistulas-2-pave-2-trials 2024-10-31T14:49:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paclitaxel-or-sirolimus-coated-balloons-used-for-arteriovenous-fistulas-2-pave-2-trials 2024-10-31T14:49:53+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-presents-latest-clinical-findings-suggesting-inhibition-of-tau 2024-10-31T14:43:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-presents-latest-clinical-findings-suggesting-inhibition-of-tau 2024-10-31T14:43:06+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-presents-data-on-benefits-of-long-term-administration-of-dual-acting-lecanemab-at 2024-10-31T14:43:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-presents-data-on-benefits-of-long-term-administration-of-dual-acting-lecanemab-at 2024-10-31T14:43:05+00:00 weekly 0.7 https://trial.medpath.com/news/biofrontera-inc-announces-highly-significant-results-in-phase-3-study-of-ameluz-globenewswire 2024-10-31T14:41:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biofrontera-inc-announces-highly-significant-results-in-phase-3-study-of-ameluz-globenewswire 2024-10-31T14:41:11+00:00 weekly 0.7 https://trial.medpath.com/news/sinaptica-s-neuromodulation-device-aces-phase-ii-alzheimer-s-trial 2024-10-31T14:30:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sinaptica-s-neuromodulation-device-aces-phase-ii-alzheimer-s-trial 2024-10-31T14:30:44+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-second-set-of-changes-to-irhythm-zio-at-to-resolve-warning-letter-massdevice 2024-10-31T14:30:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-second-set-of-changes-to-irhythm-zio-at-to-resolve-warning-letter-massdevice 2024-10-31T14:30:05+00:00 weekly 0.7 https://trial.medpath.com/news/shanghai-henlius-biotech-organon-announce-fda-acceptance-of-bla-for-hlx14 2024-10-31T14:29:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shanghai-henlius-biotech-organon-announce-fda-acceptance-of-bla-for-hlx14 2024-10-31T14:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-interpath-009-trial-of-mrna-4157-plus-pembrolizumab-for-nsclc-begins-recruitment 2024-10-31T14:16:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-interpath-009-trial-of-mrna-4157-plus-pembrolizumab-for-nsclc-begins-recruitment 2024-10-31T14:16:32+00:00 weekly 0.7 https://trial.medpath.com/news/pharmadrug-s-sairiyo-therapeutics-announces-successful-completion-of-stability-study-of 2024-10-31T13:58:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmadrug-s-sairiyo-therapeutics-announces-successful-completion-of-stability-study-of 2024-10-31T13:58:12+00:00 weekly 0.7 https://trial.medpath.com/news/ventus-therapeutics-announces-successful-completion-of-phase-1-clinical-trial-of-vent 2024-10-31T13:58:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ventus-therapeutics-announces-successful-completion-of-phase-1-clinical-trial-of-vent 2024-10-31T13:58:10+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-announces-interim-efficacy-data-and-safety-approval-for-phase-ii 2024-10-31T13:58:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-announces-interim-efficacy-data-and-safety-approval-for-phase-ii 2024-10-31T13:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/aditxt-s-target-acquisition-appili-therapeutics-announces-alignment-with-fda-on-biospace 2024-10-31T13:58:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aditxt-s-target-acquisition-appili-therapeutics-announces-alignment-with-fda-on-biospace 2024-10-31T13:58:03+00:00 weekly 0.7 https://trial.medpath.com/news/capricor-therapeutics-and-the-fda-a-daring-risky-filing-strategy-stat-news 2024-10-31T13:52:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/capricor-therapeutics-and-the-fda-a-daring-risky-filing-strategy-stat-news 2024-10-31T13:52:54+00:00 weekly 0.7 https://trial.medpath.com/news/advanced-therapies-redefine-survival-for-patients-with-breast-cancer-pharmacy-times 2024-10-31T13:48:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advanced-therapies-redefine-survival-for-patients-with-breast-cancer-pharmacy-times 2024-10-31T13:48:11+00:00 weekly 0.7 https://trial.medpath.com/news/nih-study-demonstrates-long-term-benefits-of-weight-loss-surgery-in-young-people 2024-10-31T13:42:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-study-demonstrates-long-term-benefits-of-weight-loss-surgery-in-young-people 2024-10-31T13:42:51+00:00 weekly 0.7 https://trial.medpath.com/news/the-semaglutide-drought-may-be-ending-stat-news 2024-10-31T13:37:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-semaglutide-drought-may-be-ending-stat-news 2024-10-31T13:37:13+00:00 weekly 0.7 https://trial.medpath.com/news/compass-cuts-30-of-staff-as-late-stage-psilocybin-drug-trials-face-new-delays 2024-10-31T13:32:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/compass-cuts-30-of-staff-as-late-stage-psilocybin-drug-trials-face-new-delays 2024-10-31T13:32:35+00:00 weekly 0.7 https://trial.medpath.com/news/new-breast-cancer-therapy-doubles-progression-free-survival-pf-media 2024-10-31T13:22:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-breast-cancer-therapy-doubles-progression-free-survival-pf-media 2024-10-31T13:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/study-suggests-earlier-is-better-for-heart-valve-replacement-procedures 2024-10-31T13:10:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-suggests-earlier-is-better-for-heart-valve-replacement-procedures 2024-10-31T13:10:05+00:00 weekly 0.7 https://trial.medpath.com/news/karyopharm-announces-favorable-change-in-co-primary-endpoint-for-pivotal-phase-3 2024-10-31T13:06:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/karyopharm-announces-favorable-change-in-co-primary-endpoint-for-pivotal-phase-3 2024-10-31T13:06:48+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T13:05:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T13:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/leo-pharma-continues-to-deliver-double-digit-revenue-growth-backed-by-strong-dermatology-sales 2024-10-31T13:03:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leo-pharma-continues-to-deliver-double-digit-revenue-growth-backed-by-strong-dermatology-sales 2024-10-31T13:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/naya-biosciences-to-present-translational-insights-to 2024-10-31T13:02:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/naya-biosciences-to-present-translational-insights-to 2024-10-31T13:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/aditxt-s-target-acquisition-appili-therapeutics-announces-alignment-with-fda-on-stock-titan 2024-10-31T12:55:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aditxt-s-target-acquisition-appili-therapeutics-announces-alignment-with-fda-on-stock-titan 2024-10-31T12:55:18+00:00 weekly 0.7 https://trial.medpath.com/news/uk-dementia-clinical-trial-participation-set-to-boost-by-tens-of-thousands-pharmatimes 2024-10-31T12:47:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-dementia-clinical-trial-participation-set-to-boost-by-tens-of-thousands-pharmatimes 2024-10-31T12:47:04+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-grants-accelerated-approval-to-novartis-scemblix-for-adult-patients-with-newly 2024-10-31T12:29:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-grants-accelerated-approval-to-novartis-scemblix-for-adult-patients-with-newly 2024-10-31T12:29:31+00:00 weekly 0.7 https://trial.medpath.com/news/acumen-pharmaceuticals-presents-innovative-trial-screening-advancements-morningstar 2024-10-31T12:27:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acumen-pharmaceuticals-presents-innovative-trial-screening-advancements-morningstar 2024-10-31T12:27:47+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-trial-retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine 2024-10-31T12:22:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-trial-retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine 2024-10-31T12:22:14+00:00 weekly 0.7 https://trial.medpath.com/news/anavex-s-blarcamesine-achieves-pre-specified-efficacy-in-phase-iib-iii-alzheimer-s-trial 2024-10-31T12:18:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anavex-s-blarcamesine-achieves-pre-specified-efficacy-in-phase-iib-iii-alzheimer-s-trial 2024-10-31T12:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/high-grade-cesium-results-continue-in-latest-drilling-phase-canada-newswire 2024-10-31T12:14:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-grade-cesium-results-continue-in-latest-drilling-phase-canada-newswire 2024-10-31T12:14:26+00:00 weekly 0.7 https://trial.medpath.com/news/alloplex-s-cancer-immunotherapy-shows-promise-in-phase-i-trial 2024-10-31T12:05:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alloplex-s-cancer-immunotherapy-shows-promise-in-phase-i-trial 2024-10-31T12:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-regenerative-medicine-advanced-therapy-designation-to-allo-316-in-cd70 2024-10-31T12:04:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-regenerative-medicine-advanced-therapy-designation-to-allo-316-in-cd70 2024-10-31T12:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-launches-bundled-solutions-to-support-oncology-and-vaccine-trials 2024-10-31T12:03:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medidata-launches-bundled-solutions-to-support-oncology-and-vaccine-trials 2024-10-31T12:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-announces-positive-results-from-phase-iii-pivotal-trial-sunrise-of-vyepti 2024-10-31T11:51:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lundbeck-announces-positive-results-from-phase-iii-pivotal-trial-sunrise-of-vyepti 2024-10-31T11:51:55+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-announces-positive-results-from-phase-iii-pivotal-trial-sunrise-of-vyepti-placera 2024-10-31T11:49:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lundbeck-announces-positive-results-from-phase-iii-pivotal-trial-sunrise-of-vyepti-placera 2024-10-31T11:49:02+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T11:39:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/madrigal-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-10-31T11:39:03+00:00 weekly 0.7 https://trial.medpath.com/news/palatin-completes-enrollment-in-phase-2-clinical-study-of-bremelanotide-mc4r-agonist 2024-10-31T11:36:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palatin-completes-enrollment-in-phase-2-clinical-study-of-bremelanotide-mc4r-agonist 2024-10-31T11:36:45+00:00 weekly 0.7 https://trial.medpath.com/news/palatin-completes-enrollment-in-phase-2-clinical-study-of-bremelanotide-mc4r-agonist 2024-10-31T11:36:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palatin-completes-enrollment-in-phase-2-clinical-study-of-bremelanotide-mc4r-agonist 2024-10-31T11:36:29+00:00 weekly 0.7 https://trial.medpath.com/news/avadel-pharmaceuticals-announces-favorable-ruling-in-administrative-procedure-act-litigation 2024-10-31T11:28:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avadel-pharmaceuticals-announces-favorable-ruling-in-administrative-procedure-act-litigation 2024-10-31T11:28:55+00:00 weekly 0.7 https://trial.medpath.com/news/appili-therapeutics-announces-alignment-with-fda-on-globenewswire 2024-10-31T11:19:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/appili-therapeutics-announces-alignment-with-fda-on-globenewswire 2024-10-31T11:19:26+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-reports-third-quarter-2024-globenewswire 2024-10-31T11:16:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/madrigal-pharmaceuticals-reports-third-quarter-2024-globenewswire 2024-10-31T11:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/breast-cancer-breakthrough-as-new-drug-combination-stops-disease-in-its-tracks 2024-10-31T11:15:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breast-cancer-breakthrough-as-new-drug-combination-stops-disease-in-its-tracks 2024-10-31T11:15:10+00:00 weekly 0.7 https://trial.medpath.com/news/avadel-pharmaceuticals-announces-favorable-ruling-in-globenewswire 2024-10-31T11:13:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avadel-pharmaceuticals-announces-favorable-ruling-in-globenewswire 2024-10-31T11:13:43+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-for-leukemia-treatment-becker-s-hospital-review 2024-10-31T11:02:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-for-leukemia-treatment-becker-s-hospital-review 2024-10-31T11:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/personalized-neuromodulation-treatment-significantly-slowed-alzheimer-s-progression-in 2024-10-31T11:00:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/personalized-neuromodulation-treatment-significantly-slowed-alzheimer-s-progression-in 2024-10-31T11:00:22+00:00 weekly 0.7 https://trial.medpath.com/news/syros-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-10-31T10:57:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syros-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-10-31T10:57:50+00:00 weekly 0.7 https://trial.medpath.com/news/compass-pathways-plc-sec-10-q-report-tradingview 2024-10-31T10:47:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/compass-pathways-plc-sec-10-q-report-tradingview 2024-10-31T10:47:52+00:00 weekly 0.7 https://trial.medpath.com/news/curevo-presents-positive-shingles-vaccine-outcomes-data 2024-10-31T10:37:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curevo-presents-positive-shingles-vaccine-outcomes-data 2024-10-31T10:37:54+00:00 weekly 0.7 https://trial.medpath.com/news/retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine-breakthrough 2024-10-31T10:06:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine-breakthrough 2024-10-31T10:06:49+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-trial-retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine 2024-10-31T10:06:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-trial-retraining-immune-cells-offers-new-hope-for-patients-in-personalized-medicine 2024-10-31T10:06:43+00:00 weekly 0.7 https://trial.medpath.com/news/first-site-initiated-in-australia-for-mannkind-s-phase-3-clinical-trial-evaluating-clofazimine 2024-10-31T09:48:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-site-initiated-in-australia-for-mannkind-s-phase-3-clinical-trial-evaluating-clofazimine 2024-10-31T09:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-therapeutics-announces-third-quarter-financial-results-positive-results-biospace 2024-10-31T09:48:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corcept-therapeutics-announces-third-quarter-financial-results-positive-results-biospace 2024-10-31T09:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-food-and-drug-administration-fda-grants-prolong-pharmaceuticals-fda-fast-track 2024-10-31T09:48:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-food-and-drug-administration-fda-grants-prolong-pharmaceuticals-fda-fast-track 2024-10-31T09:48:45+00:00 weekly 0.7 https://trial.medpath.com/news/noema-pharma-announces-first-patients-dosed-in-phase-2b-study-with-gemlapodect-noe 2024-10-31T09:48:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/noema-pharma-announces-first-patients-dosed-in-phase-2b-study-with-gemlapodect-noe 2024-10-31T09:48:44+00:00 weekly 0.7 https://trial.medpath.com/news/t-cell-malignancies-clinical-trial-pipeline-insights-featuring-70-companies-delveinsight 2024-10-31T09:46:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t-cell-malignancies-clinical-trial-pipeline-insights-featuring-70-companies-delveinsight 2024-10-31T09:46:47+00:00 weekly 0.7 https://trial.medpath.com/news/jpmorgan-sees-cipla-stock-upside-as-fda-approval-accelerates-gabraxane-launch 2024-10-31T09:16:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jpmorgan-sees-cipla-stock-upside-as-fda-approval-accelerates-gabraxane-launch 2024-10-31T09:16:33+00:00 weekly 0.7 https://trial.medpath.com/news/daiichi-sankyo-astrazeneca-launch-phase-iii-trials-of-datopotamab-deruxtecan-in 2024-10-31T09:06:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daiichi-sankyo-astrazeneca-launch-phase-iii-trials-of-datopotamab-deruxtecan-in 2024-10-31T09:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/powerful-new-therapy-doubles-progression-free-survival-in-advanced-breast-cancer 2024-10-31T09:00:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/powerful-new-therapy-doubles-progression-free-survival-in-advanced-breast-cancer 2024-10-31T09:00:58+00:00 weekly 0.7 https://trial.medpath.com/news/a-one-week-elderberry-juice-intervention-augments-the-fecal-microbiota-and-suggests-pubmed 2024-10-31T09:00:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-one-week-elderberry-juice-intervention-augments-the-fecal-microbiota-and-suggests-pubmed 2024-10-31T09:00:23+00:00 weekly 0.7 https://trial.medpath.com/news/protega-pharma-receives-us-fda-approval-for-roxybond-ir-10-mg-tablet-with-abuse 2024-10-31T08:59:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protega-pharma-receives-us-fda-approval-for-roxybond-ir-10-mg-tablet-with-abuse 2024-10-31T08:59:56+00:00 weekly 0.7 https://trial.medpath.com/news/anavex-s-blarcamesine-achieves-pre-specified-efficacy-in-phase-iib-iii-alzheimer-s-trial 2024-10-31T08:14:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anavex-s-blarcamesine-achieves-pre-specified-efficacy-in-phase-iib-iii-alzheimer-s-trial 2024-10-31T08:14:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-of-scemblix-for-newly-diagnosed-cml 2024-10-31T07:32:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-of-scemblix-for-newly-diagnosed-cml 2024-10-31T07:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/biofuture-2024-fda-eases-the-way-for-cell-and-gene-therapy-companies-bioworld 2024-10-31T07:30:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biofuture-2024-fda-eases-the-way-for-cell-and-gene-therapy-companies-bioworld 2024-10-31T07:30:53+00:00 weekly 0.7 https://trial.medpath.com/news/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis 2024-10-31T07:10:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis 2024-10-31T07:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/countdown-to-approval-mesoblast-readies-for-ryoncil-s-fda-milestone-sharecafe 2024-10-31T07:10:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/countdown-to-approval-mesoblast-readies-for-ryoncil-s-fda-milestone-sharecafe 2024-10-31T07:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/inventiva-announces-the-positive-recommendation-of-the-fifth-dmc-of-the-nativ3-phase-3 2024-10-31T06:45:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inventiva-announces-the-positive-recommendation-of-the-fifth-dmc-of-the-nativ3-phase-3 2024-10-31T06:45:58+00:00 weekly 0.7 https://trial.medpath.com/news/optiscan-doubles-revenue-boosts-profit-for-sep-qtr-brisbane-times 2024-10-31T06:30:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/optiscan-doubles-revenue-boosts-profit-for-sep-qtr-brisbane-times 2024-10-31T06:30:26+00:00 weekly 0.7 https://trial.medpath.com/news/chugai-files-for-additional-indication-of-tecentriq-for-the-treatment-of-extranodal-natural 2024-10-31T06:25:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chugai-files-for-additional-indication-of-tecentriq-for-the-treatment-of-extranodal-natural 2024-10-31T06:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-announces-strong-first-half-fy2024-results-and-raises-full-year-outlook 2024-10-31T06:23:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/takeda-announces-strong-first-half-fy2024-results-and-raises-full-year-outlook 2024-10-31T06:23:44+00:00 weekly 0.7 https://trial.medpath.com/news/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-roche-s-itovebi 2024-10-31T06:14:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-roche-s-itovebi 2024-10-31T06:14:12+00:00 weekly 0.7 https://trial.medpath.com/news/ttvr-with-evoque-device-linked-to-substantial-benefits-after-1-year 2024-10-31T06:13:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ttvr-with-evoque-device-linked-to-substantial-benefits-after-1-year 2024-10-31T06:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/company-announcement-ft-com-markets-data 2024-10-31T06:11:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/company-announcement-ft-com-markets-data 2024-10-31T06:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-roche-s-itovebi 2024-10-31T06:05:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-roche-s-itovebi 2024-10-31T06:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/new-three-drug-therapy-could-double-breast-cancer-survival-time-yahoo 2024-10-31T05:47:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-three-drug-therapy-could-double-breast-cancer-survival-time-yahoo 2024-10-31T05:47:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-regulations-evolve-as-science-changes-elevar-therapeutics-coo-kbr 2024-10-31T05:07:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-regulations-evolve-as-science-changes-elevar-therapeutics-coo-kbr 2024-10-31T05:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/cstone-announces-mhra-approval-of-sugemalimab-for-first-line-treatment-of-non-small 2024-10-31T05:07:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cstone-announces-mhra-approval-of-sugemalimab-for-first-line-treatment-of-non-small 2024-10-31T05:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/multidisciplinary-teams-transform-stage-3a-lung-cancer-care-with-precision-medicine-approach 2024-10-31T04:58:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multidisciplinary-teams-transform-stage-3a-lung-cancer-care-with-precision-medicine-approach 2024-10-31T04:58:00+00:00 weekly 0.7 https://trial.medpath.com/news/shuttle-pharma-doses-three-subjects-in-phase-ii-glioblastoma-treatment-trial 2024-10-31T04:55:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shuttle-pharma-doses-three-subjects-in-phase-ii-glioblastoma-treatment-trial 2024-10-31T04:55:25+00:00 weekly 0.7 https://trial.medpath.com/news/acurate-ide-trial-misses-primary-endpoint-in-all-risk-tavi-patients-tctmd-com 2024-10-31T04:45:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acurate-ide-trial-misses-primary-endpoint-in-all-risk-tavi-patients-tctmd-com 2024-10-31T04:45:01+00:00 weekly 0.7 https://trial.medpath.com/news/cipla-shares-rise-10-after-usfda-paves-way-for-abraxane-drug-launch-news18 2024-10-31T04:33:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cipla-shares-rise-10-after-usfda-paves-way-for-abraxane-drug-launch-news18 2024-10-31T04:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-presents-encouraging-data-on-bepranemab-in-early-alzheimers-disease-in-phase-2a-study-at-ctad-2024 2024-10-31T04:11:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-presents-encouraging-data-on-bepranemab-in-early-alzheimers-disease-in-phase-2a-study-at-ctad-2024 2024-10-31T04:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/nih-trial-of-rectal-microbicide-for-hiv-prevention-begins-in-the-united-states 2024-10-31T04:10:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-trial-of-rectal-microbicide-for-hiv-prevention-begins-in-the-united-states 2024-10-31T04:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/new-vaccine-production-process-could-help-in-health-emergencies 2024-10-31T04:01:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-vaccine-production-process-could-help-in-health-emergencies 2024-10-31T04:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/sichuan-kelun-biotech-s-promising-drug-gains-key-approval-markets-insider 2024-10-31T03:57:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sichuan-kelun-biotech-s-promising-drug-gains-key-approval-markets-insider 2024-10-31T03:57:40+00:00 weekly 0.7 https://trial.medpath.com/news/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis 2024-10-31T03:57:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis 2024-10-31T03:57:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-didn-t-flub-approval-in-orphan-drug-case-dc-court-says-law360-uk 2024-10-31T03:50:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-didn-t-flub-approval-in-orphan-drug-case-dc-court-says-law360-uk 2024-10-31T03:50:19+00:00 weekly 0.7 https://trial.medpath.com/news/acurate-neo2tm-aortic-valve-system-data-presented-at-late-breaking-clinical-trial 2024-10-31T03:43:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acurate-neo2tm-aortic-valve-system-data-presented-at-late-breaking-clinical-trial 2024-10-31T03:43:01+00:00 weekly 0.7 https://trial.medpath.com/news/medable-and-google-cloud-partner-to-revolutionize-digital-clinical-trial-platform-access 2024-10-31T03:36:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medable-and-google-cloud-partner-to-revolutionize-digital-clinical-trial-platform-access 2024-10-31T03:36:45+00:00 weekly 0.7 https://trial.medpath.com/news/verastem-oncology-completes-rolling-nda-submission-to-the-fda-for-avutometinib-plus-defactinib-as-a-treatment-for-recurrent-kras-mutant-low-grade-serous-ovarian-cancer 2024-10-31T03:10:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verastem-oncology-completes-rolling-nda-submission-to-the-fda-for-avutometinib-plus-defactinib-as-a-treatment-for-recurrent-kras-mutant-low-grade-serous-ovarian-cancer 2024-10-31T03:10:54+00:00 weekly 0.7 https://trial.medpath.com/news/2024-ncoda-summit-highlights-advances-in-cancer-care-and-treatment-innovation 2024-10-31T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-ncoda-summit-highlights-advances-in-cancer-care-and-treatment-innovation 2024-10-31T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/l-k-biomed-earns-fda-approval-for-new-lumbar-spine-device 2024-10-31T02:51:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/l-k-biomed-earns-fda-approval-for-new-lumbar-spine-device 2024-10-31T02:51:40+00:00 weekly 0.7 https://trial.medpath.com/news/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis-morningstar 2024-10-31T02:40:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis-morningstar 2024-10-31T02:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/clofutriben-shows-promise-in-trial-for-endogenous-cushing-s-syndrome 2024-10-31T02:37:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clofutriben-shows-promise-in-trial-for-endogenous-cushing-s-syndrome 2024-10-31T02:37:18+00:00 weekly 0.7 https://trial.medpath.com/news/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis 2024-10-31T02:27:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abionic-s-capsule-psp-receives-fda-approval-for-early-detection-of-sepsis 2024-10-31T02:27:12+00:00 weekly 0.7 https://trial.medpath.com/news/nature-cell-s-jointstem-receives-fda-rmat-designation-hiteunyuseu 2024-10-31T02:22:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nature-cell-s-jointstem-receives-fda-rmat-designation-hiteunyuseu 2024-10-31T02:22:27+00:00 weekly 0.7 https://trial.medpath.com/news/cutia-therapeutics-announces-trial-success-for-fat-reduction-drug-markets-insider 2024-10-31T02:16:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cutia-therapeutics-announces-trial-success-for-fat-reduction-drug-markets-insider 2024-10-31T02:16:39+00:00 weekly 0.7 https://trial.medpath.com/news/c-o-r-r-e-c-t-i-o-n-akeso-inc-company-announcement-ft-com-markets-data 2024-10-31T01:35:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/c-o-r-r-e-c-t-i-o-n-akeso-inc-company-announcement-ft-com-markets-data 2024-10-31T01:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/countdown-to-approval-mesoblast-readies-for-ryoncil-s-fda-milestone-finance-news-network 2024-10-31T01:23:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/countdown-to-approval-mesoblast-readies-for-ryoncil-s-fda-milestone-finance-news-network 2024-10-31T01:23:39+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-alzheimer-treatment-through-gamma-oscillation-stimulation-ralph-kern-md-mhsc 2024-10-31T01:12:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancing-alzheimer-treatment-through-gamma-oscillation-stimulation-ralph-kern-md-mhsc 2024-10-31T01:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-plus-chemotherapy-enhances-outcomes-in-early-stage-tnbc 2024-10-31T01:04:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pembrolizumab-plus-chemotherapy-enhances-outcomes-in-early-stage-tnbc 2024-10-31T01:04:05+00:00 weekly 0.7 https://trial.medpath.com/news/it-was-a-revolution-the-forgotten-australian-whose-medical-breakthrough-saved-millions-of-lives 2024-10-31T01:02:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/it-was-a-revolution-the-forgotten-australian-whose-medical-breakthrough-saved-millions-of-lives 2024-10-31T01:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combined-with 2024-10-31T00:53:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akeso-announces-first-patient-enrollment-in-phase-3-trial-of-ivonescimab-combined-with 2024-10-31T00:53:38+00:00 weekly 0.7 https://trial.medpath.com/news/nda-submitted-for-3-month-formulation-of-leuprolide-mesylate-for-advanced-prostate-cancer 2024-10-31T00:37:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nda-submitted-for-3-month-formulation-of-leuprolide-mesylate-for-advanced-prostate-cancer 2024-10-31T00:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/three-drug-treatment-for-breast-cancer-can-delay-the-spread-of-disease-daily-mail 2024-10-31T00:35:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-drug-treatment-for-breast-cancer-can-delay-the-spread-of-disease-daily-mail 2024-10-31T00:35:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-approval-for-shorla-s-jylamvo-for-paediatric-patients 2024-10-31T00:07:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-expands-approval-for-shorla-s-jylamvo-for-paediatric-patients 2024-10-31T00:07:04+00:00 weekly 0.7 https://trial.medpath.com/news/triumvira-immunologics-to-present-new-clinical-data-from-ongoing-claudin-18-2-phase-1 2024-10-31T00:01:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/triumvira-immunologics-to-present-new-clinical-data-from-ongoing-claudin-18-2-phase-1 2024-10-31T00:01:11+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-presents-data-on-benefits-of-long-term-administration-globenewswire 2024-10-30T23:39:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-presents-data-on-benefits-of-long-term-administration-globenewswire 2024-10-30T23:39:26+00:00 weekly 0.7 https://trial.medpath.com/news/appendix-4c-quarterly-activity-report-for-quarter-ended-september-30-2024-quantisnow 2024-10-30T23:28:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/appendix-4c-quarterly-activity-report-for-quarter-ended-september-30-2024-quantisnow 2024-10-30T23:28:28+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-shares-positive-phase-iii-data-of-mirikizumab-for-the-treatment-of-crohn-s-disease 2024-10-30T23:24:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-shares-positive-phase-iii-data-of-mirikizumab-for-the-treatment-of-crohn-s-disease 2024-10-30T23:24:37+00:00 weekly 0.7 https://trial.medpath.com/news/appendix-4c-quarterly-activity-report-for-quarter-ended-september-30-2024-globenewswire 2024-10-30T23:13:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/appendix-4c-quarterly-activity-report-for-quarter-ended-september-30-2024-globenewswire 2024-10-30T23:13:31+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-secures-first-line-cml-expansion-for-scemblix-projects-3b-in-peak-sales 2024-10-30T23:12:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-secures-first-line-cml-expansion-for-scemblix-projects-3b-in-peak-sales 2024-10-30T23:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-staff-not-quite-sold-on-sotagliflozin-for-t1d-patients-with-ckd-medpage-today 2024-10-30T23:06:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-staff-not-quite-sold-on-sotagliflozin-for-t1d-patients-with-ckd-medpage-today 2024-10-30T23:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/new-hope-for-breast-cancer-patients-after-huge-therapy-breakthrough-mirror-online 2024-10-30T22:59:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-hope-for-breast-cancer-patients-after-huge-therapy-breakthrough-mirror-online 2024-10-30T22:59:31+00:00 weekly 0.7 https://trial.medpath.com/news/leukemia-drug-shows-promise-in-dementia-with-lewy-bodies-medpage-today 2024-10-30T22:57:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leukemia-drug-shows-promise-in-dementia-with-lewy-bodies-medpage-today 2024-10-30T22:57:42+00:00 weekly 0.7 https://trial.medpath.com/news/three-drug-mix-doubles-survival-time-for-advanced-breast-cancer-the-times 2024-10-30T22:34:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-drug-mix-doubles-survival-time-for-advanced-breast-cancer-the-times 2024-10-30T22:34:11+00:00 weekly 0.7 https://trial.medpath.com/news/karyopharm-to-host-investor-event-with-leading-myelofibrosis-kols-and-provide-a 2024-10-30T22:30:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/karyopharm-to-host-investor-event-with-leading-myelofibrosis-kols-and-provide-a 2024-10-30T22:30:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-warning-on-biozorb-markers-after-recall-due-to-patient-complications 2024-10-30T22:19:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-warning-on-biozorb-markers-after-recall-due-to-patient-complications 2024-10-30T22:19:34+00:00 weekly 0.7 https://trial.medpath.com/news/intravesical-mitomycin-demonstrates-significant-duration-of-response-in-nmibc 2024-10-30T22:19:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intravesical-mitomycin-demonstrates-significant-duration-of-response-in-nmibc 2024-10-30T22:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-study-of-upar-pet-ct-for-staging-of-primary-breast-cancer-in-comparison-with 2024-10-30T22:08:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-study-of-upar-pet-ct-for-staging-of-primary-breast-cancer-in-comparison-with 2024-10-30T22:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trailrunner-alz-3-to-test-effects-of-igg1-monoclonal-antibody-remternetug-in 2024-10-30T22:08:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trailrunner-alz-3-to-test-effects-of-igg1-monoclonal-antibody-remternetug-in 2024-10-30T22:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/3-to-know-nch-partners-for-clinical-trials-student-dies-more-marco-eagle 2024-10-30T22:06:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3-to-know-nch-partners-for-clinical-trials-student-dies-more-marco-eagle 2024-10-30T22:06:10+00:00 weekly 0.7 https://trial.medpath.com/news/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-genentech-s 2024-10-30T21:19:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-genentech-s 2024-10-30T21:19:54+00:00 weekly 0.7 https://trial.medpath.com/news/irhythm-technologies-receives-fda-510-k-clearance-for-design-modifications-to-its-zio 2024-10-30T21:19:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/irhythm-technologies-receives-fda-510-k-clearance-for-design-modifications-to-its-zio 2024-10-30T21:19:52+00:00 weekly 0.7 https://trial.medpath.com/news/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-genentech-s 2024-10-30T21:16:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for-genentech-s 2024-10-30T21:16:11+00:00 weekly 0.7 https://trial.medpath.com/news/huge-breakthrough-in-breast-cancer-drug-therapy-doubles-survival-time-the-independent 2024-10-30T21:11:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/huge-breakthrough-in-breast-cancer-drug-therapy-doubles-survival-time-the-independent 2024-10-30T21:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/lexeo-therapeutics-scores-positive-early-data-for-apoe4-alzheimer-s-gene-therapy 2024-10-30T21:07:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexeo-therapeutics-scores-positive-early-data-for-apoe4-alzheimer-s-gene-therapy 2024-10-30T21:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/breast-cancer-survival-time-doubles-with-three-drug-therapy-trial-finds-the-telegraph 2024-10-30T21:03:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breast-cancer-survival-time-doubles-with-three-drug-therapy-trial-finds-the-telegraph 2024-10-30T21:03:41+00:00 weekly 0.7 https://trial.medpath.com/news/wegovy-reduces-knee-pain-in-osteoarthritis-patients-with-obesity-study-finds-stat-news 2024-10-30T21:02:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wegovy-reduces-knee-pain-in-osteoarthritis-patients-with-obesity-study-finds-stat-news 2024-10-30T21:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-receives-fda-approval-of-mapping-and-ablation-system-and-catheter-daic 2024-10-30T20:56:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-receives-fda-approval-of-mapping-and-ablation-system-and-catheter-daic 2024-10-30T20:56:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advises-against-use-of-biozorb-markers-in-breast-cancer-and-other-indications 2024-10-30T20:51:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-advises-against-use-of-biozorb-markers-in-breast-cancer-and-other-indications 2024-10-30T20:51:11+00:00 weekly 0.7 https://trial.medpath.com/news/fda-receives-nda-for-3-month-version-of-leuprolide-mesylate-for-advanced-prostate-cancer 2024-10-30T20:51:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-receives-nda-for-3-month-version-of-leuprolide-mesylate-for-advanced-prostate-cancer 2024-10-30T20:51:10+00:00 weekly 0.7 https://trial.medpath.com/news/wave-life-sciences-highlights-growing-pipeline-at-research-globenewswire 2024-10-30T20:49:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wave-life-sciences-highlights-growing-pipeline-at-research-globenewswire 2024-10-30T20:49:18+00:00 weekly 0.7 https://trial.medpath.com/news/risk-of-aria-e-in-donanemab-attenuated-through-new-enhanced-titration-method-of-delivery 2024-10-30T20:44:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/risk-of-aria-e-in-donanemab-attenuated-through-new-enhanced-titration-method-of-delivery 2024-10-30T20:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/neurovoices-anne-marie-morse-do-faasm-on-the-impact-of-the-once-nightly-sodium 2024-10-30T20:44:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurovoices-anne-marie-morse-do-faasm-on-the-impact-of-the-once-nightly-sodium 2024-10-30T20:44:36+00:00 weekly 0.7 https://trial.medpath.com/news/azenta-obtains-regulatory-approval-for-clinical-long-read-whole-genome-sequencing-test 2024-10-30T20:33:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/azenta-obtains-regulatory-approval-for-clinical-long-read-whole-genome-sequencing-test 2024-10-30T20:33:46+00:00 weekly 0.7 https://trial.medpath.com/news/doctor-given-24-months-to-live-reveals-how-she-reversed-her-cancer-with-breakthrough-therapy 2024-10-30T20:19:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/doctor-given-24-months-to-live-reveals-how-she-reversed-her-cancer-with-breakthrough-therapy 2024-10-30T20:19:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-abbott-cgms-for-use-during-medical-imaging-drug-delivery-business 2024-10-30T20:16:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-abbott-cgms-for-use-during-medical-imaging-drug-delivery-business 2024-10-30T20:16:02+00:00 weekly 0.7 https://trial.medpath.com/news/galapagos-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-10-30T20:15:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/galapagos-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-10-30T20:15:12+00:00 weekly 0.7 https://trial.medpath.com/news/inventiva-announces-the-positive-recommendation-of-the-fifth-dmc-of-the-nativ3-phase-3 2024-10-30T20:15:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inventiva-announces-the-positive-recommendation-of-the-fifth-dmc-of-the-nativ3-phase-3 2024-10-30T20:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-another-new-antibiotic-becker-s-hospital-review 2024-10-30T20:13:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-another-new-antibiotic-becker-s-hospital-review 2024-10-30T20:13:48+00:00 weekly 0.7 https://trial.medpath.com/news/new-insights-in-cancer-care-shared-at-annual-oncology-update-2024-inventum 2024-10-30T20:11:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-insights-in-cancer-care-shared-at-annual-oncology-update-2024-inventum 2024-10-30T20:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/biosimilar-aflibercept-p041-as-effective-safe-as-originator-in-namd 2024-10-30T20:04:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biosimilar-aflibercept-p041-as-effective-safe-as-originator-in-namd 2024-10-30T20:04:16+00:00 weekly 0.7 https://trial.medpath.com/news/with-fresh-funding-houston-cancer-fighting-cell-therapy-gears-up-for-continued-clinical-trials 2024-10-30T19:53:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/with-fresh-funding-houston-cancer-fighting-cell-therapy-gears-up-for-continued-clinical-trials 2024-10-30T19:53:57+00:00 weekly 0.7 https://trial.medpath.com/news/low-dose-dobutamine-in-acute-myocardial-infarction-with-intermediate-to-high-risk-of-trials 2024-10-30T19:42:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/low-dose-dobutamine-in-acute-myocardial-infarction-with-intermediate-to-high-risk-of-trials 2024-10-30T19:42:46+00:00 weekly 0.7 https://trial.medpath.com/news/ohsu-researchers-identify-gene-that-could-be-key-to-future-hiv-vaccine 2024-10-30T19:36:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ohsu-researchers-identify-gene-that-could-be-key-to-future-hiv-vaccine 2024-10-30T19:36:06+00:00 weekly 0.7 https://trial.medpath.com/news/mineralys-therapeutics-completes-enrollment-ahead-of-schedule-in-launch-htn-the-biospace 2024-10-30T19:35:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mineralys-therapeutics-completes-enrollment-ahead-of-schedule-in-launch-htn-the-biospace 2024-10-30T19:35:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-biologic-license-application-for-biosimilar-denosumab-pharmacy-times 2024-10-30T19:27:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-biologic-license-application-for-biosimilar-denosumab-pharmacy-times 2024-10-30T19:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/october-2024-fda-approvals-for-oncology 2024-10-30T19:06:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/october-2024-fda-approvals-for-oncology 2024-10-30T19:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-scemblix-secures-fda-accelerated-approval-for-chronic-myeloid-leukaemia 2024-10-30T18:48:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-scemblix-secures-fda-accelerated-approval-for-chronic-myeloid-leukaemia 2024-10-30T18:48:22+00:00 weekly 0.7 https://trial.medpath.com/news/how-cidara-got-its-molecule-back-life-science-leader 2024-10-30T18:42:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-cidara-got-its-molecule-back-life-science-leader 2024-10-30T18:42:30+00:00 weekly 0.7 https://trial.medpath.com/news/health-rounds-adaptable-implant-may-be-improvement-over-heart-stents 2024-10-30T18:38:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-rounds-adaptable-implant-may-be-improvement-over-heart-stents 2024-10-30T18:38:21+00:00 weekly 0.7 https://trial.medpath.com/news/swiss-moves-and-approvals-national-bank-and-novartis-steal-the-show-finimize 2024-10-30T18:34:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/swiss-moves-and-approvals-national-bank-and-novartis-steal-the-show-finimize 2024-10-30T18:34:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-asciminib-for-chronic-myeloid-leukemia-healio 2024-10-30T18:33:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-asciminib-for-chronic-myeloid-leukemia-healio 2024-10-30T18:33:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-jylamvo-approval-to-include-polyarticular-juvenile-idiopathic-arthritis-all 2024-10-30T18:33:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-expands-jylamvo-approval-to-include-polyarticular-juvenile-idiopathic-arthritis-all 2024-10-30T18:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/ready-to-use-3-month-leuprolide-depot-formulation-nears-fda-approval 2024-10-30T18:31:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ready-to-use-3-month-leuprolide-depot-formulation-nears-fda-approval 2024-10-30T18:31:43+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-acurate-neo2-tavr-misses-primary-endpoint-in-ide-trial-massdevice 2024-10-30T18:20:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boston-scientific-acurate-neo2-tavr-misses-primary-endpoint-in-ide-trial-massdevice 2024-10-30T18:20:04+00:00 weekly 0.7 https://trial.medpath.com/news/uproleselan-combo-does-not-improve-efs-vs-chemo-in-newly-diagnosed-aml 2024-10-30T18:09:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uproleselan-combo-does-not-improve-efs-vs-chemo-in-newly-diagnosed-aml 2024-10-30T18:09:53+00:00 weekly 0.7 https://trial.medpath.com/news/a-collaborative-approach-to-pancreatic-cancer-michigan-medicine 2024-10-30T18:03:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-collaborative-approach-to-pancreatic-cancer-michigan-medicine 2024-10-30T18:03:00+00:00 weekly 0.7 https://trial.medpath.com/news/avidity-biosciences-pursues-potential-accelerated-approval-path-with-initiation-of-biomarker 2024-10-30T18:01:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avidity-biosciences-pursues-potential-accelerated-approval-path-with-initiation-of-biomarker 2024-10-30T18:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/heartlung-ai-tool-receives-fda-breakthrough-ai-clearance-daic 2024-10-30T17:57:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heartlung-ai-tool-receives-fda-breakthrough-ai-clearance-daic 2024-10-30T17:57:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-protega-s-roxybond-10-mg-abuse-deterrent-opioid-contract-pharma 2024-10-30T17:56:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-protega-s-roxybond-10-mg-abuse-deterrent-opioid-contract-pharma 2024-10-30T17:56:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-anti-tfpi-antibody-for-haemophilia-a-and-b-nature 2024-10-30T17:30:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-anti-tfpi-antibody-for-haemophilia-a-and-b-nature 2024-10-30T17:30:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-pi3ka-inhibitor-that-does-double-duty-as-a-degrader-nature 2024-10-30T17:30:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-pi3ka-inhibitor-that-does-double-duty-as-a-degrader-nature 2024-10-30T17:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-plans-to-begin-advertising-weight-loss-drug-zepbound-yahoo-finance 2024-10-30T17:06:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-plans-to-begin-advertising-weight-loss-drug-zepbound-yahoo-finance 2024-10-30T17:06:37+00:00 weekly 0.7 https://trial.medpath.com/news/histomonosis-a-deadly-turkey-disease-researched-with-new-3-2-million-fda-grant 2024-10-30T17:05:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/histomonosis-a-deadly-turkey-disease-researched-with-new-3-2-million-fda-grant 2024-10-30T17:05:57+00:00 weekly 0.7 https://trial.medpath.com/news/tropion-lung01-update-dato-dxd-shows-activity-in-previously-treated-advanced 2024-10-30T16:51:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tropion-lung01-update-dato-dxd-shows-activity-in-previously-treated-advanced 2024-10-30T16:51:44+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-gets-fda-okay-for-frontline-use-of-scemblix-in-cml-pharmaphorum 2024-10-30T16:50:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-gets-fda-okay-for-frontline-use-of-scemblix-in-cml-pharmaphorum 2024-10-30T16:50:12+00:00 weekly 0.7 https://trial.medpath.com/news/small-molecule-drug-triggers-rapid-cell-death-in-cancer-models-medical-xpress 2024-10-30T16:29:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/small-molecule-drug-triggers-rapid-cell-death-in-cancer-models-medical-xpress 2024-10-30T16:29:53+00:00 weekly 0.7 https://trial.medpath.com/news/south-west-researchers-seek-participants-for-flu-vaccine-trial-ivybridge-today 2024-10-30T16:29:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/south-west-researchers-seek-participants-for-flu-vaccine-trial-ivybridge-today 2024-10-30T16:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/active-biotech-s-tasquinimod-study-receives-green-light-from-ema-marketscreener 2024-10-30T16:02:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/active-biotech-s-tasquinimod-study-receives-green-light-from-ema-marketscreener 2024-10-30T16:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-novartis-scemblix-for-newly-diagnosed-chromosome 2024-10-30T16:01:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-novartis-scemblix-for-newly-diagnosed-chromosome 2024-10-30T16:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/sure1-and-reassure-trials-paved-way-for-fda-approval-of-orlynvah-contagion-live 2024-10-30T15:53:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sure1-and-reassure-trials-paved-way-for-fda-approval-of-orlynvah-contagion-live 2024-10-30T15:53:58+00:00 weekly 0.7 https://trial.medpath.com/news/a-virtual-breakthrough-series-collaborative-for-missed-test-results-jama-network 2024-10-30T15:44:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-virtual-breakthrough-series-collaborative-for-missed-test-results-jama-network 2024-10-30T15:44:39+00:00 weekly 0.7 https://trial.medpath.com/news/neurosense-fda-to-meet-on-phase-3-plans-for-primec-in-als-als-news-today 2024-10-30T15:42:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurosense-fda-to-meet-on-phase-3-plans-for-primec-in-als-als-news-today 2024-10-30T15:42:07+00:00 weekly 0.7 https://trial.medpath.com/news/latest-updates-of-viva-biotech-s-portfolio-companies-morningstar 2024-10-30T15:14:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/latest-updates-of-viva-biotech-s-portfolio-companies-morningstar 2024-10-30T15:14:40+00:00 weekly 0.7 https://trial.medpath.com/news/novel-treatment-options-for-children-and-young-adults-with-relapsed-osteosarcoma 2024-10-30T15:11:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-treatment-options-for-children-and-young-adults-with-relapsed-osteosarcoma 2024-10-30T15:11:07+00:00 weekly 0.7 https://trial.medpath.com/news/methotrexate-s-approval-expanded-to-include-pediatric-all-oncology-nursing-news 2024-10-30T15:09:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/methotrexate-s-approval-expanded-to-include-pediatric-all-oncology-nursing-news 2024-10-30T15:09:45+00:00 weekly 0.7 https://trial.medpath.com/news/triscend-ii-trial-demonstrates-superior-clinical-and-quality-of-life-benefits-with-edwards 2024-10-30T15:04:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/triscend-ii-trial-demonstrates-superior-clinical-and-quality-of-life-benefits-with-edwards 2024-10-30T15:04:50+00:00 weekly 0.7 https://trial.medpath.com/news/early-data-from-roche-s-alzheimer-s-therapy-show-it-s-hitting-targets-stat-news 2024-10-30T14:46:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-data-from-roche-s-alzheimer-s-therapy-show-it-s-hitting-targets-stat-news 2024-10-30T14:46:04+00:00 weekly 0.7 https://trial.medpath.com/news/tharimmune-receives-positive-regulatory-feedback-from-ema-for-th104-clinical-program 2024-10-30T14:42:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tharimmune-receives-positive-regulatory-feedback-from-ema-for-th104-clinical-program 2024-10-30T14:42:40+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatment-shrinks-man-s-aggressive-brain-tumour-by-half-in-breakthrough-trial 2024-10-30T14:41:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-treatment-shrinks-man-s-aggressive-brain-tumour-by-half-in-breakthrough-trial 2024-10-30T14:41:17+00:00 weekly 0.7 https://trial.medpath.com/news/use-of-aumolertinib-extends-progression-free-survival-in-stage-iii-egfr-mutated-nsclc 2024-10-30T14:36:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/use-of-aumolertinib-extends-progression-free-survival-in-stage-iii-egfr-mutated-nsclc 2024-10-30T14:36:35+00:00 weekly 0.7 https://trial.medpath.com/news/fasenra-granted-approval-in-eu-for-hard-to-treat-egpa-patients-anca-vasculitis-news 2024-10-30T14:00:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fasenra-granted-approval-in-eu-for-hard-to-treat-egpa-patients-anca-vasculitis-news 2024-10-30T14:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/can-roswell-park-s-promising-brain-cancer-vaccine-work-for-children-and-young-adults 2024-10-30T13:58:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-roswell-park-s-promising-brain-cancer-vaccine-work-for-children-and-young-adults 2024-10-30T13:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/biomea-awaits-2-data-readouts-of-diabetes-studies-can-the-stock-get-its-mojo-back 2024-10-30T13:58:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomea-awaits-2-data-readouts-of-diabetes-studies-can-the-stock-get-its-mojo-back 2024-10-30T13:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-acquires-aliada-and-alzheimer-s-candidate-for-1-4b-inside-precision-medicine 2024-10-30T13:57:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-acquires-aliada-and-alzheimer-s-candidate-for-1-4b-inside-precision-medicine 2024-10-30T13:57:14+00:00 weekly 0.7 https://trial.medpath.com/news/imunon-to-present-phase-2-data-of-imnn-001-in-treatment-of-globenewswire 2024-10-30T13:53:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imunon-to-present-phase-2-data-of-imnn-001-in-treatment-of-globenewswire 2024-10-30T13:53:36+00:00 weekly 0.7 https://trial.medpath.com/news/scilex-announces-successful-end-of-phase-ii-meeting-with-fda-markets-insider 2024-10-30T13:45:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scilex-announces-successful-end-of-phase-ii-meeting-with-fda-markets-insider 2024-10-30T13:45:42+00:00 weekly 0.7 https://trial.medpath.com/news/spero-s-stock-slides-after-antibiotic-flops-in-phase-ii-trial-yahoo-finance 2024-10-30T13:43:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spero-s-stock-slides-after-antibiotic-flops-in-phase-ii-trial-yahoo-finance 2024-10-30T13:43:25+00:00 weekly 0.7 https://trial.medpath.com/news/spero-s-stock-slides-after-antibiotic-flops-in-phase-ii-trial-pharmaceutical-technology 2024-10-30T13:41:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spero-s-stock-slides-after-antibiotic-flops-in-phase-ii-trial-pharmaceutical-technology 2024-10-30T13:41:09+00:00 weekly 0.7 https://trial.medpath.com/news/imunon-to-present-phase-2-data-of-imnn-001-in-treatment-of-newly-diagnosed-ovarian 2024-10-30T13:22:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imunon-to-present-phase-2-data-of-imnn-001-in-treatment-of-newly-diagnosed-ovarian 2024-10-30T13:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/new-fda-approved-approach-to-treating-liver-cancer-kplc 2024-10-30T13:04:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-fda-approved-approach-to-treating-liver-cancer-kplc 2024-10-30T13:04:57+00:00 weekly 0.7 https://trial.medpath.com/news/spero-s-stock-slides-after-antibiotic-flops-in-phase-ii-trial 2024-10-30T13:00:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spero-s-stock-slides-after-antibiotic-flops-in-phase-ii-trial 2024-10-30T13:00:59+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-s-denifanstat-enters-phase-iii-trials-for-mash-treatment 2024-10-30T13:00:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sagimet-s-denifanstat-enters-phase-iii-trials-for-mash-treatment 2024-10-30T13:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/zai-lab-presents-positive-outcomes-from-karxt-phase-iii-trial-for-schizophrenia 2024-10-30T13:00:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zai-lab-presents-positive-outcomes-from-karxt-phase-iii-trial-for-schizophrenia 2024-10-30T13:00:55+00:00 weekly 0.7 https://trial.medpath.com/news/tharimmune-receives-positive-regulatory-feedback-from-ema-for-th104-clinical-program 2024-10-30T12:54:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tharimmune-receives-positive-regulatory-feedback-from-ema-for-th104-clinical-program 2024-10-30T12:54:20+00:00 weekly 0.7 https://trial.medpath.com/news/beta-bionics-launches-ilet-pump-with-abbott-freestyle-libre-3-plus 2024-10-30T12:51:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beta-bionics-launches-ilet-pump-with-abbott-freestyle-libre-3-plus 2024-10-30T12:51:10+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-appoints-dr-melissa-palmer-m-d-as-lead-consultant-in-hepatology 2024-10-30T12:50:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytodyn-appoints-dr-melissa-palmer-m-d-as-lead-consultant-in-hepatology 2024-10-30T12:50:50+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-food-and-drug-administration-fda-grants-prolong-pharmaceuticals-fda-fast-track 2024-10-30T12:48:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-food-and-drug-administration-fda-grants-prolong-pharmaceuticals-fda-fast-track 2024-10-30T12:48:01+00:00 weekly 0.7 https://trial.medpath.com/news/a-doctor-weighs-in-on-anti-agers-using-rapamycin-to-extend-their-lives-cnbc 2024-10-30T12:47:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-doctor-weighs-in-on-anti-agers-using-rapamycin-to-extend-their-lives-cnbc 2024-10-30T12:47:11+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-s-denifanstat-enters-phase-iii-trials-for-mash-treatment-yahoo-finance 2024-10-30T12:45:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sagimet-s-denifanstat-enters-phase-iii-trials-for-mash-treatment-yahoo-finance 2024-10-30T12:45:53+00:00 weekly 0.7 https://trial.medpath.com/news/synox-therapeutics-adds-new-investor-and-capital-to-series-b-financing-raising-total-to 2024-10-30T12:45:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/synox-therapeutics-adds-new-investor-and-capital-to-series-b-financing-raising-total-to 2024-10-30T12:45:24+00:00 weekly 0.7 https://trial.medpath.com/news/tiziana-life-sciences-announces-positive-results-from-globenewswire 2024-10-30T12:32:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tiziana-life-sciences-announces-positive-results-from-globenewswire 2024-10-30T12:32:03+00:00 weekly 0.7 https://trial.medpath.com/news/promis-neurosciences-presents-positive-data-from-pmn310-phase1a-clinical-trial-morningstar 2024-10-30T12:30:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promis-neurosciences-presents-positive-data-from-pmn310-phase1a-clinical-trial-morningstar 2024-10-30T12:30:38+00:00 weekly 0.7 https://trial.medpath.com/news/three-phase-3-trials-of-datopotamab-deruxtecan-based-combinations-initiated-in-patients 2024-10-30T12:30:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-phase-3-trials-of-datopotamab-deruxtecan-based-combinations-initiated-in-patients 2024-10-30T12:30:12+00:00 weekly 0.7 https://trial.medpath.com/news/avidity-biosciences-advances-fshd-therapy-trial-by-investing-com 2024-10-30T12:29:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avidity-biosciences-advances-fshd-therapy-trial-by-investing-com 2024-10-30T12:29:40+00:00 weekly 0.7 https://trial.medpath.com/news/scilex-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-scilex-holding-company-biospace 2024-10-30T12:09:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scilex-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-scilex-holding-company-biospace 2024-10-30T12:09:31+00:00 weekly 0.7 https://trial.medpath.com/news/promis-neurosciences-presents-positive-data-from-pmn310-globenewswire 2024-10-30T12:08:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promis-neurosciences-presents-positive-data-from-pmn310-globenewswire 2024-10-30T12:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/avidity-biosciences-pursues-potential-accelerated-approval-path-with-initiation-of-biomarker 2024-10-30T12:07:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avidity-biosciences-pursues-potential-accelerated-approval-path-with-initiation-of-biomarker 2024-10-30T12:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/hamlet-biopharma-interview-with-chairman-professor-catharina-svanborg-about-the-pulse-2-0 2024-10-30T12:05:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hamlet-biopharma-interview-with-chairman-professor-catharina-svanborg-about-the-pulse-2-0 2024-10-30T12:05:29+00:00 weekly 0.7 https://trial.medpath.com/news/dassault-systemes-collaboration-yields-breakthrough-guide-for-using-virtual-twins-in-clinical-trials 2024-10-30T12:01:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dassault-systemes-collaboration-yields-breakthrough-guide-for-using-virtual-twins-in-clinical-trials 2024-10-30T12:01:35+00:00 weekly 0.7 https://trial.medpath.com/news/summit-therapeutics-reports-operational-progress-and-financial-results-for-the-morningstar 2024-10-30T11:58:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/summit-therapeutics-reports-operational-progress-and-financial-results-for-the-morningstar 2024-10-30T11:58:38+00:00 weekly 0.7 https://trial.medpath.com/news/evan-dellon-md-mph-promising-phase-3-cendakimab-data-for-eosinophilic-esophagitis 2024-10-30T11:34:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evan-dellon-md-mph-promising-phase-3-cendakimab-data-for-eosinophilic-esophagitis 2024-10-30T11:34:55+00:00 weekly 0.7 https://trial.medpath.com/news/tissue-agnostic-cancer-therapies-herald-new-era-in-precision-oncology-expert-says 2024-10-30T11:28:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tissue-agnostic-cancer-therapies-herald-new-era-in-precision-oncology-expert-says 2024-10-30T11:28:49+00:00 weekly 0.7 https://trial.medpath.com/news/larimar-therapeutics-reports-third-quarter-2024-operating-and-financial-results 2024-10-30T11:21:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/larimar-therapeutics-reports-third-quarter-2024-operating-and-financial-results 2024-10-30T11:21:05+00:00 weekly 0.7 https://trial.medpath.com/news/ananda-developments-interims-for-the-six-months-ended-31-july-2024-research-tree 2024-10-30T11:15:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ananda-developments-interims-for-the-six-months-ended-31-july-2024-research-tree 2024-10-30T11:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/synox-therapeutics-adds-new-investor-and-capital-to-series-globenewswire 2024-10-30T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/synox-therapeutics-adds-new-investor-and-capital-to-series-globenewswire 2024-10-30T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/larimar-therapeutics-reports-third-quarter-2024-operating-and-financial-results 2024-10-30T11:01:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/larimar-therapeutics-reports-third-quarter-2024-operating-and-financial-results 2024-10-30T11:01:43+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-scemblix-gains-fda-approval-for-leukaemia-treatment 2024-10-30T10:52:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-scemblix-gains-fda-approval-for-leukaemia-treatment 2024-10-30T10:52:13+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-on-track-to-deliver-2024-outlooks-with-further-good-progress-made-in-r-d 2024-10-30T10:51:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-on-track-to-deliver-2024-outlooks-with-further-good-progress-made-in-r-d 2024-10-30T10:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-a-multicomponent-intervention-for-managing-kidney-outcomes-among-patients-trials 2024-10-30T10:22:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-a-multicomponent-intervention-for-managing-kidney-outcomes-among-patients-trials 2024-10-30T10:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/scilex-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-scilex-holding-company-morningstar 2024-10-30T10:12:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scilex-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-scilex-holding-company-morningstar 2024-10-30T10:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/scilex-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-scilex-holding-company-stock-titan 2024-10-30T10:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scilex-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-scilex-holding-company-stock-titan 2024-10-30T10:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/scilex-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-globenewswire 2024-10-30T10:03:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scilex-pharmaceuticals-inc-a-wholly-owned-subsidiary-of-globenewswire 2024-10-30T10:03:11+00:00 weekly 0.7 https://trial.medpath.com/news/active-biotech-s-clinical-trial-of-tasquinimod-in-myelofibrosis-approved-in-europe-placera 2024-10-30T09:49:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/active-biotech-s-clinical-trial-of-tasquinimod-in-myelofibrosis-approved-in-europe-placera 2024-10-30T09:49:19+00:00 weekly 0.7 https://trial.medpath.com/news/chop-receives-10-million-grant-for-project-that-uses-clinical-data-analysis-to-combat-rare-diseases 2024-10-30T09:41:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chop-receives-10-million-grant-for-project-that-uses-clinical-data-analysis-to-combat-rare-diseases 2024-10-30T09:41:17+00:00 weekly 0.7 https://trial.medpath.com/news/a-prospective-open-label-phase-iib-iii-study-to-evaluate-the-risk-of-tls-and-optimization 2024-10-30T09:40:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-prospective-open-label-phase-iib-iii-study-to-evaluate-the-risk-of-tls-and-optimization 2024-10-30T09:40:40+00:00 weekly 0.7 https://trial.medpath.com/news/allogene-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat 2024-10-30T09:16:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allogene-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat 2024-10-30T09:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/zai-lab-reports-positive-topline-data-from-phase-3-bridging-trial-evaluating-karxt-for-the 2024-10-30T09:15:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zai-lab-reports-positive-topline-data-from-phase-3-bridging-trial-evaluating-karxt-for-the 2024-10-30T09:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/grifols-receives-fda-approval-to-treat-surgical-bleeding-in-pediatric-patients-with-its-fibrin 2024-10-30T09:15:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grifols-receives-fda-approval-to-treat-surgical-bleeding-in-pediatric-patients-with-its-fibrin 2024-10-30T09:15:54+00:00 weekly 0.7 https://trial.medpath.com/news/roche-and-dyno-therapeutics-form-1b-alliance-to-develop-ai-powered-gene-therapies-for-neurological-disorders 2024-10-30T09:15:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-and-dyno-therapeutics-form-1b-alliance-to-develop-ai-powered-gene-therapies-for-neurological-disorders 2024-10-30T09:15:14+00:00 weekly 0.7 https://trial.medpath.com/news/insights-for-psychedelic-stakeholders-from-recent-fda-public-meeting-on-advancing-lexology 2024-10-30T08:48:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insights-for-psychedelic-stakeholders-from-recent-fda-public-meeting-on-advancing-lexology 2024-10-30T08:48:17+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-stocks-facing-fda-decision-in-november-2024-rttnews 2024-10-30T08:43:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-stocks-facing-fda-decision-in-november-2024-rttnews 2024-10-30T08:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/methotrexate-gains-expanded-approval-for-pediatric-acute-lymphoblastic-leukemia 2024-10-30T08:36:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/methotrexate-gains-expanded-approval-for-pediatric-acute-lymphoblastic-leukemia 2024-10-30T08:36:08+00:00 weekly 0.7 https://trial.medpath.com/news/pharmaceutical-industry-faces-widespread-layoffs-amid-patent-cliffs-and-economic-uncertainty 2024-10-30T08:17:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmaceutical-industry-faces-widespread-layoffs-amid-patent-cliffs-and-economic-uncertainty 2024-10-30T08:17:41+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-plc-confirms-2024-guidance-q3-dividend-of-15p-declared-directorstalk-interviews 2024-10-30T08:12:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-plc-confirms-2024-guidance-q3-dividend-of-15p-declared-directorstalk-interviews 2024-10-30T08:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/astellas-withdraws-izervay-s-european-approval-filing 2024-10-30T08:02:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astellas-withdraws-izervay-s-european-approval-filing 2024-10-30T08:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/october-30-2024-in-this-week-s-pct-grand-rounds-the-chi-ron-study-of-adults-with 2024-10-30T08:01:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/october-30-2024-in-this-week-s-pct-grand-rounds-the-chi-ron-study-of-adults-with 2024-10-30T08:01:24+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-cogstate-partner-to-transform-clinical-trials-in-neurology-bernama 2024-10-30T07:50:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medidata-cogstate-partner-to-transform-clinical-trials-in-neurology-bernama 2024-10-30T07:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/novel-therapies-transform-treatment-landscape-for-liver-and-biliary-tract-cancers 2024-10-30T07:33:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-therapies-transform-treatment-landscape-for-liver-and-biliary-tract-cancers 2024-10-30T07:33:31+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-scemblix-r-fda-approved-in-newly-diagnosed-cml-offering-superior-efficacy-and 2024-10-30T07:18:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-scemblix-r-fda-approved-in-newly-diagnosed-cml-offering-superior-efficacy-and 2024-10-30T07:18:16+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-reports-sharp-decline-in-vaccine-sales-as-rsv-shot-arexvy-falls-72-in-q3 2024-10-30T07:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-reports-sharp-decline-in-vaccine-sales-as-rsv-shot-arexvy-falls-72-in-q3 2024-10-30T07:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-better-drug-may-make-transplants-more-successful-yahoo 2024-10-30T06:54:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-better-drug-may-make-transplants-more-successful-yahoo 2024-10-30T06:54:57+00:00 weekly 0.7 https://trial.medpath.com/news/patient-researcher-s-journey-leads-to-breakthrough-treatment-for-rare-light-sensitivity-disorder 2024-10-30T06:53:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-researcher-s-journey-leads-to-breakthrough-treatment-for-rare-light-sensitivity-disorder 2024-10-30T06:53:58+00:00 weekly 0.7 https://trial.medpath.com/news/inari-medical-s-flowtriever-meets-primary-endpoint-in-pulmonary-embolism-trial 2024-10-30T06:43:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inari-medical-s-flowtriever-meets-primary-endpoint-in-pulmonary-embolism-trial 2024-10-30T06:43:06+00:00 weekly 0.7 https://trial.medpath.com/news/irlab-publishes-interim-report-for-the-period-january-september-2024-morningstar 2024-10-30T06:40:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/irlab-publishes-interim-report-for-the-period-january-september-2024-morningstar 2024-10-30T06:40:50+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-begin-phase-3-trial-assessing-adjuvant-v940-with-pembrolizumab-to-treat 2024-10-30T05:40:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-begin-phase-3-trial-assessing-adjuvant-v940-with-pembrolizumab-to-treat 2024-10-30T05:40:18+00:00 weekly 0.7 https://trial.medpath.com/news/well-health-and-healwell-ai-work-to-expand-clinical-trial-access-mugglehead-magazine 2024-10-30T05:11:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/well-health-and-healwell-ai-work-to-expand-clinical-trial-access-mugglehead-magazine 2024-10-30T05:11:18+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-announces-fda-acceptance-of-translarna-nda-resubmission 2024-10-30T05:10:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-therapeutics-announces-fda-acceptance-of-translarna-nda-resubmission 2024-10-30T05:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/evolution-of-precision-medicine-reshapes-cancer-treatment-landscape-expert-highlights-future-of-blood-based-monitoring 2024-10-30T05:00:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evolution-of-precision-medicine-reshapes-cancer-treatment-landscape-expert-highlights-future-of-blood-based-monitoring 2024-10-30T05:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/usp-standards-and-engineering-controls-essential-for-safe-hazardous-drug-compounding 2024-10-30T04:58:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/usp-standards-and-engineering-controls-essential-for-safe-hazardous-drug-compounding 2024-10-30T04:58:00+00:00 weekly 0.7 https://trial.medpath.com/news/adagrasib-in-krystal-12-has-broken-the-krasg12c-enigma-code-in-non-sma-lctt 2024-10-30T04:44:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adagrasib-in-krystal-12-has-broken-the-krasg12c-enigma-code-in-non-sma-lctt 2024-10-30T04:44:57+00:00 weekly 0.7 https://trial.medpath.com/news/dr-dhakal-on-notable-multiple-myeloma-trials-presented-in-2024-onclive 2024-10-30T04:37:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-dhakal-on-notable-multiple-myeloma-trials-presented-in-2024-onclive 2024-10-30T04:37:35+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-scemblix-receives-accelerated-fda-approval-for-newly-diagnosed-ph-cml-in-adults 2024-10-30T04:29:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-scemblix-receives-accelerated-fda-approval-for-newly-diagnosed-ph-cml-in-adults 2024-10-30T04:29:56+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-to-acquire-biotechnology-company-aliada-therapeutics-for-1-4-billion-pharmabiz 2024-10-30T03:30:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-to-acquire-biotechnology-company-aliada-therapeutics-for-1-4-billion-pharmabiz 2024-10-30T03:30:56+00:00 weekly 0.7 https://trial.medpath.com/news/epilepsy-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-10-30T03:18:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/epilepsy-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-10-30T03:18:21+00:00 weekly 0.7 https://trial.medpath.com/news/ynhh-performs-first-fda-approved-tambe-procedure-in-connecticut-yale-daily-news 2024-10-30T03:11:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ynhh-performs-first-fda-approved-tambe-procedure-in-connecticut-yale-daily-news 2024-10-30T03:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-approval-for-jylamvo-to-children-with-acute-lymphoblastic-leukemia 2024-10-30T03:11:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-expands-approval-for-jylamvo-to-children-with-acute-lymphoblastic-leukemia 2024-10-30T03:11:49+00:00 weekly 0.7 https://trial.medpath.com/news/satsuma-pharmaceuticals-and-snbl-resubmits-the-new-drug-application-for-sts101-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine-with-or-without-aura 2024-10-30T03:10:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/satsuma-pharmaceuticals-and-snbl-resubmits-the-new-drug-application-for-sts101-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine-with-or-without-aura 2024-10-30T03:10:02+00:00 weekly 0.7 https://trial.medpath.com/news/monte-rosa-novartis-partner-to-advance-molecular-glue-degraders-contract-pharma 2024-10-30T03:00:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/monte-rosa-novartis-partner-to-advance-molecular-glue-degraders-contract-pharma 2024-10-30T03:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/first-participants-dosed-in-trial-of-long-acting-malaria-preventative-clinical-trials-arena 2024-10-30T02:30:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-participants-dosed-in-trial-of-long-acting-malaria-preventative-clinical-trials-arena 2024-10-30T02:30:51+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-raises-2024-earnings-outlook-as-new-drug-portfolio-shows-promise 2024-10-30T02:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-raises-2024-earnings-outlook-as-new-drug-portfolio-shows-promise 2024-10-30T02:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/shuttle-pharmaceuticals-holdings-inc-announces-pricing-of-4-5-million-public-offering 2024-10-30T01:24:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shuttle-pharmaceuticals-holdings-inc-announces-pricing-of-4-5-million-public-offering 2024-10-30T01:24:56+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-scemblix-r-fda-approved-in-newly-diagnosed-cml-offering-superior-efficacy-and 2024-10-30T01:02:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-scemblix-r-fda-approved-in-newly-diagnosed-cml-offering-superior-efficacy-and 2024-10-30T01:02:10+00:00 weekly 0.7 https://trial.medpath.com/news/nektar-announces-publication-in-nature-communications-of-results-from-phase-1b-studies 2024-10-30T01:01:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nektar-announces-publication-in-nature-communications-of-results-from-phase-1b-studies 2024-10-30T01:01:01+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-dedicated-prior-authorization-teams-and-care-management-homes-accelerate-ibd-treatment-access 2024-10-30T01:00:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-shows-dedicated-prior-authorization-teams-and-care-management-homes-accelerate-ibd-treatment-access 2024-10-30T01:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/biofuture-2024-charting-the-future-for-glp-1s-bioworld 2024-10-30T00:52:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biofuture-2024-charting-the-future-for-glp-1s-bioworld 2024-10-30T00:52:58+00:00 weekly 0.7 https://trial.medpath.com/news/coya-sinks-on-phase-ii-alzheimer-s-data-advances-combo-strategy-bioworld 2024-10-30T00:52:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/coya-sinks-on-phase-ii-alzheimer-s-data-advances-combo-strategy-bioworld 2024-10-30T00:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-dose-for-abuse-deterrent-oxycodone-healio 2024-10-30T00:24:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-dose-for-abuse-deterrent-oxycodone-healio 2024-10-30T00:24:39+00:00 weekly 0.7 https://trial.medpath.com/news/three-phase-3-trials-of-datopotamab-deruxtecan-based-combinations-initiated-in-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer 2024-10-30T00:10:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-phase-3-trials-of-datopotamab-deruxtecan-based-combinations-initiated-in-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer 2024-10-30T00:10:40+00:00 weekly 0.7 https://trial.medpath.com/news/machine-learning-optimizes-non-invasive-brain-stimulation-for-depression-treatment 2024-10-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/machine-learning-optimizes-non-invasive-brain-stimulation-for-depression-treatment 2024-10-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-protega-pharmaceuticals-roxybond-for-severe-pain-management 2024-10-29T23:53:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-protega-pharmaceuticals-roxybond-for-severe-pain-management 2024-10-29T23:53:57+00:00 weekly 0.7 https://trial.medpath.com/news/data-driven-approaches-to-accelerate-clinical-trial-diversity-astrazeneca 2024-10-29T23:16:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-driven-approaches-to-accelerate-clinical-trial-diversity-astrazeneca 2024-10-29T23:16:29+00:00 weekly 0.7 https://trial.medpath.com/news/actuate-to-participate-in-lantern-s-pharma-webinar-on-ai-driven-drug-development 2024-10-29T22:41:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actuate-to-participate-in-lantern-s-pharma-webinar-on-ai-driven-drug-development 2024-10-29T22:41:47+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-co-escapes-investor-suit-over-drug-approval-lies-law360 2024-10-29T22:38:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biopharma-co-escapes-investor-suit-over-drug-approval-lies-law360 2024-10-29T22:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/novel-drug-for-chronic-inducible-urticaria-delivers-in-mid-stage-trial-medpage-today 2024-10-29T22:37:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-drug-for-chronic-inducible-urticaria-delivers-in-mid-stage-trial-medpage-today 2024-10-29T22:37:34+00:00 weekly 0.7 https://trial.medpath.com/news/elixir-medical-has-positive-data-for-drug-eluting-bioadaptive-implant-massdevice 2024-10-29T22:31:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elixir-medical-has-positive-data-for-drug-eluting-bioadaptive-implant-massdevice 2024-10-29T22:31:22+00:00 weekly 0.7 https://trial.medpath.com/news/sonablate-enrolls-first-patient-in-incompetent-vein-ablation-clinical-trial-massdevice 2024-10-29T22:31:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sonablate-enrolls-first-patient-in-incompetent-vein-ablation-clinical-trial-massdevice 2024-10-29T22:31:22+00:00 weekly 0.7 https://trial.medpath.com/news/nektar-announces-publication-in-nature-communications-of-results-from-phase-1b-studies-of-rezpegaldesleukin-in-two-inflammatory-skin-diseases 2024-10-29T22:10:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nektar-announces-publication-in-nature-communications-of-results-from-phase-1b-studies-of-rezpegaldesleukin-in-two-inflammatory-skin-diseases 2024-10-29T22:10:56+00:00 weekly 0.7 https://trial.medpath.com/news/abeona-therapeutics-completes-pz-cel-biologics-license-application-resubmission-to-u-s-food-and-drug-administration 2024-10-29T22:10:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abeona-therapeutics-completes-pz-cel-biologics-license-application-resubmission-to-u-s-food-and-drug-administration 2024-10-29T22:10:43+00:00 weekly 0.7 https://trial.medpath.com/news/nccn-guideline-update-recommends-adjuvant-ribociclib-plus-ai-in-hr-her2-onclive 2024-10-29T22:09:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nccn-guideline-update-recommends-adjuvant-ribociclib-plus-ai-in-hr-her2-onclive 2024-10-29T22:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-takes-part-in-new-phase-1-clinical-trial-for-patients-with-recurrent-glioblastoma 2024-10-29T21:51:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-takes-part-in-new-phase-1-clinical-trial-for-patients-with-recurrent-glioblastoma 2024-10-29T21:51:15+00:00 weekly 0.7 https://trial.medpath.com/news/colchicine-falls-flat-in-large-heart-attack-trial-convincing-cardiologists-to-stay-away 2024-10-29T21:49:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/colchicine-falls-flat-in-large-heart-attack-trial-convincing-cardiologists-to-stay-away 2024-10-29T21:49:32+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-s-sotagliflozin-returns-to-us-fda-panel-with-narrowed-indication 2024-10-29T21:29:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-s-sotagliflozin-returns-to-us-fda-panel-with-narrowed-indication 2024-10-29T21:29:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-asciminib-in-ph-cml-in-chronic-phase-cancer-network 2024-10-29T20:59:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-asciminib-in-ph-cml-in-chronic-phase-cancer-network 2024-10-29T20:59:01+00:00 weekly 0.7 https://trial.medpath.com/news/invivyd-announces-phase-3-exploratory-clinical-efficacy-data-regarding-pemgarda-prel 2024-10-29T20:55:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/invivyd-announces-phase-3-exploratory-clinical-efficacy-data-regarding-pemgarda-prel 2024-10-29T20:55:56+00:00 weekly 0.7 https://trial.medpath.com/news/newsweek-s-top-dfw-hospitals-and-tcu-and-uta-s-joint-md-phd-program-d-magazine 2024-10-29T20:54:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/newsweek-s-top-dfw-hospitals-and-tcu-and-uta-s-joint-md-phd-program-d-magazine 2024-10-29T20:54:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-asciminib-for-newly-diagnosed-ph-chronic-phase 2024-10-29T20:53:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-asciminib-for-newly-diagnosed-ph-chronic-phase 2024-10-29T20:53:42+00:00 weekly 0.7 https://trial.medpath.com/news/i-m-one-of-the-first-americans-to-be-cured-of-type-1-diabetes-thanks-to-a-breakthrough-therapy 2024-10-29T20:42:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-m-one-of-the-first-americans-to-be-cured-of-type-1-diabetes-thanks-to-a-breakthrough-therapy 2024-10-29T20:42:54+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-asciminib-for-adult-patients-with-newly-diagnosed-ph 2024-10-29T20:38:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-asciminib-for-adult-patients-with-newly-diagnosed-ph 2024-10-29T20:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/zai-lab-reports-positive-topline-data-from-phase-3-bridging-trial-evaluating-karxt-for-the 2024-10-29T20:21:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zai-lab-reports-positive-topline-data-from-phase-3-bridging-trial-evaluating-karxt-for-the 2024-10-29T20:21:25+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-new-procedure-eliminates-the-need-for-insulin-in-less-than-an-hour 2024-10-29T20:19:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-new-procedure-eliminates-the-need-for-insulin-in-less-than-an-hour 2024-10-29T20:19:28+00:00 weekly 0.7 https://trial.medpath.com/news/new-device-delivers-antibiotics-directly-to-wounds-in-dogs-and-horses-dvm360 2024-10-29T20:19:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-device-delivers-antibiotics-directly-to-wounds-in-dogs-and-horses-dvm360 2024-10-29T20:19:05+00:00 weekly 0.7 https://trial.medpath.com/news/eledon-pharmaceuticals-announces-positive-initial-data-from-subjects-with-type-1-diabetes 2024-10-29T20:11:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eledon-pharmaceuticals-announces-positive-initial-data-from-subjects-with-type-1-diabetes 2024-10-29T20:11:52+00:00 weekly 0.7 https://trial.medpath.com/news/alvotech-teva-obtain-fda-nod-for-new-selarsdi-indication-drug-store-news 2024-10-29T20:09:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alvotech-teva-obtain-fda-nod-for-new-selarsdi-indication-drug-store-news 2024-10-29T20:09:06+00:00 weekly 0.7 https://trial.medpath.com/news/cytexortho-gets-fda-approval-for-first-in-human-trial-of-absorbable-hip-implants 2024-10-29T19:41:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytexortho-gets-fda-approval-for-first-in-human-trial-of-absorbable-hip-implants 2024-10-29T19:41:53+00:00 weekly 0.7 https://trial.medpath.com/news/nkgen-biotech-presents-phase-1-2a-troculeucel-data-in-alzheimer-s-disease-at-the-17th 2024-10-29T19:40:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nkgen-biotech-presents-phase-1-2a-troculeucel-data-in-alzheimer-s-disease-at-the-17th 2024-10-29T19:40:36+00:00 weekly 0.7 https://trial.medpath.com/news/corxel-and-lenz-therapeutics-announce-positive-topline-data-from-phase-3-presbyopia 2024-10-29T19:22:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corxel-and-lenz-therapeutics-announce-positive-topline-data-from-phase-3-presbyopia 2024-10-29T19:22:37+00:00 weekly 0.7 https://trial.medpath.com/news/neuralink-competitor-restores-vision-in-blind-patients-with-eye-implant-futurism 2024-10-29T19:21:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuralink-competitor-restores-vision-in-blind-patients-with-eye-implant-futurism 2024-10-29T19:21:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-regenerative-medicine-advanced-therapy-designation-to-allo-316-for-rcc 2024-10-29T19:15:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-regenerative-medicine-advanced-therapy-designation-to-allo-316-for-rcc 2024-10-29T19:15:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-abuse-deterrent-alternative-for-severe-pain-management 2024-10-29T19:05:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-abuse-deterrent-alternative-for-severe-pain-management 2024-10-29T19:05:53+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-quarterly-activities-report-q1-fy25-globenewswire 2024-10-29T18:50:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-quarterly-activities-report-q1-fy25-globenewswire 2024-10-29T18:50:46+00:00 weekly 0.7 https://trial.medpath.com/news/a-better-drug-may-make-transplants-more-successful-time 2024-10-29T18:49:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-better-drug-may-make-transplants-more-successful-time 2024-10-29T18:49:24+00:00 weekly 0.7 https://trial.medpath.com/news/new-jama-study-shows-text-messages-can-be-ineffective-as-medication-refill-reminders 2024-10-29T18:26:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-jama-study-shows-text-messages-can-be-ineffective-as-medication-refill-reminders 2024-10-29T18:26:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-scemblix-for-some-with-newly-diagnosed-chronic-myeloid-leukemia 2024-10-29T18:21:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-scemblix-for-some-with-newly-diagnosed-chronic-myeloid-leukemia 2024-10-29T18:21:57+00:00 weekly 0.7 https://trial.medpath.com/news/shionogi-announces-global-phase-3-trial-demonstrates-post-exposure-prophylactic-use-of 2024-10-29T18:21:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shionogi-announces-global-phase-3-trial-demonstrates-post-exposure-prophylactic-use-of 2024-10-29T18:21:04+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-asciminib-for-newly-diagnosed-chronic-myeloid-leukemia 2024-10-29T18:20:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-asciminib-for-newly-diagnosed-chronic-myeloid-leukemia 2024-10-29T18:20:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-asciminib-in-newly-diagnosed-ph-cml-in-chronic-phase 2024-10-29T18:18:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-asciminib-in-newly-diagnosed-ph-cml-in-chronic-phase 2024-10-29T18:18:54+00:00 weekly 0.7 https://trial.medpath.com/news/asciminib-gets-accelerated-approval-for-ph-cml-oncology-nursing-news 2024-10-29T17:59:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asciminib-gets-accelerated-approval-for-ph-cml-oncology-nursing-news 2024-10-29T17:59:08+00:00 weekly 0.7 https://trial.medpath.com/news/cognition-therapeutics-reports-potential-alzheimer-s-treatment-breakthrough-by-investing-com 2024-10-29T17:58:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cognition-therapeutics-reports-potential-alzheimer-s-treatment-breakthrough-by-investing-com 2024-10-29T17:58:17+00:00 weekly 0.7 https://trial.medpath.com/news/micro-cap-company-is-soaring-on-phase-2-trial-update-the-globe-and-mail 2024-10-29T17:45:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/micro-cap-company-is-soaring-on-phase-2-trial-update-the-globe-and-mail 2024-10-29T17:45:41+00:00 weekly 0.7 https://trial.medpath.com/news/rallybio-announces-approval-of-clinical-trial-applications-for-phase-2-trial-of-rlyb212-in 2024-10-29T17:43:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rallybio-announces-approval-of-clinical-trial-applications-for-phase-2-trial-of-rlyb212-in 2024-10-29T17:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/shuttle-pharma-doses-first-patients-in-phase-2-clinical-trial-of-ropidoxuridine-for-biospace 2024-10-29T17:43:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shuttle-pharma-doses-first-patients-in-phase-2-clinical-trial-of-ropidoxuridine-for-biospace 2024-10-29T17:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/valbiotis-announces-interim-financial-statements-and-strategic-developments 2024-10-29T17:42:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valbiotis-announces-interim-financial-statements-and-strategic-developments 2024-10-29T17:42:04+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-and-msd-begin-trial-of-mrna-4157-and-keytruda-combination-for-lung-cancer 2024-10-29T17:35:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-and-msd-begin-trial-of-mrna-4157-and-keytruda-combination-for-lung-cancer 2024-10-29T17:35:37+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-abuse-deterrent-10-mg-oxycodone-hydrochloride-for-severe-pain 2024-10-29T17:07:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-abuse-deterrent-10-mg-oxycodone-hydrochloride-for-severe-pain 2024-10-29T17:07:12+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-the-benefits-of-nab-sirolimus-in-advanced-pecoma-treatment 2024-10-29T17:03:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exploring-the-benefits-of-nab-sirolimus-in-advanced-pecoma-treatment 2024-10-29T17:03:49+00:00 weekly 0.7 https://trial.medpath.com/news/ide397-shows-early-antitumor-activity-safety-in-mtap-deletion-urothelial-cancer-and-nsclc 2024-10-29T17:03:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ide397-shows-early-antitumor-activity-safety-in-mtap-deletion-urothelial-cancer-and-nsclc 2024-10-29T17:03:45+00:00 weekly 0.7 https://trial.medpath.com/news/well-health-and-healwell-ai-expand-clinical-trials-tipranks-com 2024-10-29T16:53:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/well-health-and-healwell-ai-expand-clinical-trials-tipranks-com 2024-10-29T16:53:19+00:00 weekly 0.7 https://trial.medpath.com/news/new-test-tailors-leukemia-treatment-boosts-survival-odds-helsinki-times 2024-10-29T16:35:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-test-tailors-leukemia-treatment-boosts-survival-odds-helsinki-times 2024-10-29T16:35:42+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-to-seek-fda-approval-after-small-bore-impella-heart-pump-hits-trial-goal 2024-10-29T16:28:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-to-seek-fda-approval-after-small-bore-impella-heart-pump-hits-trial-goal 2024-10-29T16:28:54+00:00 weekly 0.7 https://trial.medpath.com/news/naobios-and-sumagen-achieve-milestone-in-hiv-1-vaccine-production-contract-pharma 2024-10-29T16:21:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/naobios-and-sumagen-achieve-milestone-in-hiv-1-vaccine-production-contract-pharma 2024-10-29T16:21:41+00:00 weekly 0.7 https://trial.medpath.com/news/recursion-advances-ai-based-c-diff-candidate-to-phase-ii 2024-10-29T16:15:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recursion-advances-ai-based-c-diff-candidate-to-phase-ii 2024-10-29T16:15:19+00:00 weekly 0.7 https://trial.medpath.com/news/distant-recurrence-risk-among-women-with-early-breast-cancer-enrolled-in-clinical-trials 2024-10-29T16:09:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/distant-recurrence-risk-among-women-with-early-breast-cancer-enrolled-in-clinical-trials 2024-10-29T16:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-says-modified-dosing-of-its-alzheimer-s-drug-kisunla-may-be-safer-stat-news 2024-10-29T16:05:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-says-modified-dosing-of-its-alzheimer-s-drug-kisunla-may-be-safer-stat-news 2024-10-29T16:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/mosaic-8b-pan-sarbecovirus-vaccine-enters-development 2024-10-29T15:46:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mosaic-8b-pan-sarbecovirus-vaccine-enters-development 2024-10-29T15:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/start-and-fundacion-rioja-salud-to-expand-access-to-cancer-drug-trials-in-spain-yahoo 2024-10-29T15:39:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/start-and-fundacion-rioja-salud-to-expand-access-to-cancer-drug-trials-in-spain-yahoo 2024-10-29T15:39:25+00:00 weekly 0.7 https://trial.medpath.com/news/start-and-fundacion-rioja-salud-to-expand-access-to-cancer-drug-trials-in-spain 2024-10-29T15:35:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/start-and-fundacion-rioja-salud-to-expand-access-to-cancer-drug-trials-in-spain 2024-10-29T15:35:26+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-to-seek-fda-approval-after-small-bore-impella-heart-pump-hits-trial-goal-medtech-dive 2024-10-29T15:30:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-to-seek-fda-approval-after-small-bore-impella-heart-pump-hits-trial-goal-medtech-dive 2024-10-29T15:30:16+00:00 weekly 0.7 https://trial.medpath.com/news/psma-pet-ct-can-reveal-prostate-cancer-recurrences-before-biochemical-criteria-met 2024-10-29T15:19:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psma-pet-ct-can-reveal-prostate-cancer-recurrences-before-biochemical-criteria-met 2024-10-29T15:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/bavarian-eyes-mpox-vaccine-label-expansion-to-include-toddlers-kickstarts-phase-ii-trial 2024-10-29T15:18:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bavarian-eyes-mpox-vaccine-label-expansion-to-include-toddlers-kickstarts-phase-ii-trial 2024-10-29T15:18:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-fibrin-sealant-to-control-surgical-bleeding-in-pediatric-patients 2024-10-29T15:15:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-fibrin-sealant-to-control-surgical-bleeding-in-pediatric-patients 2024-10-29T15:15:49+00:00 weekly 0.7 https://trial.medpath.com/news/shorla-oncology-announces-u-s-food-and-drug-administration-fda-expanded-approval 2024-10-29T15:02:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shorla-oncology-announces-u-s-food-and-drug-administration-fda-expanded-approval 2024-10-29T15:02:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-approval-to-oxycodone-hydrochloride-immediate-release-tablets-pharmacy-times 2024-10-29T14:59:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-approval-to-oxycodone-hydrochloride-immediate-release-tablets-pharmacy-times 2024-10-29T14:59:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-methotrexate-indication-to-included-children-with-acute-lymphoblastic-leukemia 2024-10-29T14:59:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-expands-methotrexate-indication-to-included-children-with-acute-lymphoblastic-leukemia 2024-10-29T14:59:20+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-bimekizumab-data-offer-new-hope-for-hs-management 2024-10-29T14:56:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-bimekizumab-data-offer-new-hope-for-hs-management 2024-10-29T14:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-to-ask-for-fda-approval-of-vatiquinone-for-fa-by-year-s-end-friedreich-s-ataxia-news 2024-10-29T14:54:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-to-ask-for-fda-approval-of-vatiquinone-for-fa-by-year-s-end-friedreich-s-ataxia-news 2024-10-29T14:54:02+00:00 weekly 0.7 https://trial.medpath.com/news/longeveron-r-presents-lomecel-btm-data-for-alzheimer-s-globenewswire 2024-10-29T14:49:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longeveron-r-presents-lomecel-btm-data-for-alzheimer-s-globenewswire 2024-10-29T14:49:57+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-inks-150m-molecular-glue-deal-with-monte-rosa-inside-precision-medicine 2024-10-29T14:41:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-inks-150m-molecular-glue-deal-with-monte-rosa-inside-precision-medicine 2024-10-29T14:41:35+00:00 weekly 0.7 https://trial.medpath.com/news/bavarian-eyes-mpox-vaccine-label-expansion-to-include-toddlers-kickstarts-phase-ii-trial 2024-10-29T14:39:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bavarian-eyes-mpox-vaccine-label-expansion-to-include-toddlers-kickstarts-phase-ii-trial 2024-10-29T14:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/painchek-prepares-fda-de-novo-submission-for-smartphone-app-following-successful-us 2024-10-29T14:31:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/painchek-prepares-fda-de-novo-submission-for-smartphone-app-following-successful-us 2024-10-29T14:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/gemvax-announces-topline-results-from-phase-2a-progressive-supranuclear-palsy 2024-10-29T14:29:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gemvax-announces-topline-results-from-phase-2a-progressive-supranuclear-palsy 2024-10-29T14:29:59+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-presents-data-from-fabhalta-at-asn-kidney-week-2024-pharmabiz 2024-10-29T14:29:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-presents-data-from-fabhalta-at-asn-kidney-week-2024-pharmabiz 2024-10-29T14:29:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-approval-for-methotrexate-in-pediatric-all-pjia-indications-cancer-network 2024-10-29T14:18:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-expands-approval-for-methotrexate-in-pediatric-all-pjia-indications-cancer-network 2024-10-29T14:18:16+00:00 weekly 0.7 https://trial.medpath.com/news/lifechanging-new-cancer-therapy-kills-99-of-cancer-cells-the-brighter-side-of-news 2024-10-29T14:17:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lifechanging-new-cancer-therapy-kills-99-of-cancer-cells-the-brighter-side-of-news 2024-10-29T14:17:06+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-sciences-to-withdraw-sacituzumab-govitecan-bladder-cancer-approval-status 2024-10-29T14:03:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-sciences-to-withdraw-sacituzumab-govitecan-bladder-cancer-approval-status 2024-10-29T14:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/mira-pharmaceuticals-shares-surge-40-after-ketamir-2-excels-in-gurufocus 2024-10-29T14:03:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mira-pharmaceuticals-shares-surge-40-after-ketamir-2-excels-in-gurufocus 2024-10-29T14:03:22+00:00 weekly 0.7 https://trial.medpath.com/news/microbial-dynamics-and-pulmonary-immune-responses-in-covid-19-secondary-bacterial-pneumonia 2024-10-29T13:46:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/microbial-dynamics-and-pulmonary-immune-responses-in-covid-19-secondary-bacterial-pneumonia 2024-10-29T13:46:02+00:00 weekly 0.7 https://trial.medpath.com/news/digital-avatar-therapy-for-distressing-voices-in-psychosis-the-phase-2-3-avatar2-trial 2024-10-29T13:43:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-avatar-therapy-for-distressing-voices-in-psychosis-the-phase-2-3-avatar2-trial 2024-10-29T13:43:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-paragonix-kidneyvault-portable-renal-perfusion-system-massdevice 2024-10-29T13:41:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-paragonix-kidneyvault-portable-renal-perfusion-system-massdevice 2024-10-29T13:41:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-approval-for-jylamvo-oral-methotrexate-solution-in-all-targeted-oncology 2024-10-29T13:33:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-expands-approval-for-jylamvo-oral-methotrexate-solution-in-all-targeted-oncology 2024-10-29T13:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-and-lilly-both-boast-il-23-inhibitor-efficacy-in-crohn-s-disease-yahoo-finance 2024-10-29T13:23:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-and-lilly-both-boast-il-23-inhibitor-efficacy-in-crohn-s-disease-yahoo-finance 2024-10-29T13:23:59+00:00 weekly 0.7 https://trial.medpath.com/news/heartlung-technologies-receives-fda-breakthrough-status-and-marketing-authorization 2024-10-29T13:20:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heartlung-technologies-receives-fda-breakthrough-status-and-marketing-authorization 2024-10-29T13:20:51+00:00 weekly 0.7 https://trial.medpath.com/news/bavarian-eyes-mpox-vaccine-label-expansion-to-include-toddlers-kickstarts-phase-ii-trial 2024-10-29T13:18:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bavarian-eyes-mpox-vaccine-label-expansion-to-include-toddlers-kickstarts-phase-ii-trial 2024-10-29T13:18:08+00:00 weekly 0.7 https://trial.medpath.com/news/canadian-health-tech-companies-developing-ai-enhanced-clinical-trials-stockhouse 2024-10-29T13:17:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/canadian-health-tech-companies-developing-ai-enhanced-clinical-trials-stockhouse 2024-10-29T13:17:17+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-medications-show-promise-as-first-drug-therapy-for-sleep-apnea 2024-10-29T13:11:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-medications-show-promise-as-first-drug-therapy-for-sleep-apnea 2024-10-29T13:11:51+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-and-lilly-both-unveil-il-23-inhibitor-efficacy-in-crohn-s-disease-clinical-trials-arena 2024-10-29T13:11:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-and-lilly-both-unveil-il-23-inhibitor-efficacy-in-crohn-s-disease-clinical-trials-arena 2024-10-29T13:11:26+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-and-cogstate-strike-strategic-partnership-transforming-clinical-trials-in 2024-10-29T13:09:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medidata-and-cogstate-strike-strategic-partnership-transforming-clinical-trials-in 2024-10-29T13:09:36+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-receives-fda-clearance-for-qiastat-dx-mini-panel-to-globenewswire 2024-10-29T13:08:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qiagen-receives-fda-clearance-for-qiastat-dx-mini-panel-to-globenewswire 2024-10-29T13:08:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-approval-of-methotrexate-to-include-pediatric-acute-lymphoblastic-leukemia 2024-10-29T13:03:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-expands-approval-of-methotrexate-to-include-pediatric-acute-lymphoblastic-leukemia 2024-10-29T13:03:43+00:00 weekly 0.7 https://trial.medpath.com/news/bavarian-eyes-mpox-vaccine-label-expansion-to-include-toddlers-kickstarts-phase-ii-trial 2024-10-29T13:01:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bavarian-eyes-mpox-vaccine-label-expansion-to-include-toddlers-kickstarts-phase-ii-trial 2024-10-29T13:01:41+00:00 weekly 0.7 https://trial.medpath.com/news/rallybio-to-begin-first-clinical-trial-for-prevention-of-rare-pregnancy-blood-disorder 2024-10-29T13:01:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rallybio-to-begin-first-clinical-trial-for-prevention-of-rare-pregnancy-blood-disorder 2024-10-29T13:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/ec-approves-expanded-use-of-edurant-for-younger-paediatric-hiv-1-patients 2024-10-29T13:00:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ec-approves-expanded-use-of-edurant-for-younger-paediatric-hiv-1-patients 2024-10-29T13:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/chiesi-announces-phase-3-results-from-enzyme-replacement-study-pharmafile 2024-10-29T12:53:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chiesi-announces-phase-3-results-from-enzyme-replacement-study-pharmafile 2024-10-29T12:53:47+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-tells-bloomberg-approval-received-to-launch-mounjaro-in-hong-kong 2024-10-29T12:50:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-tells-bloomberg-approval-received-to-launch-mounjaro-in-hong-kong 2024-10-29T12:50:02+00:00 weekly 0.7 https://trial.medpath.com/news/upcoming-fda-advisory-panel-for-icecure-s-prosense-r-marketing-authorization-receives 2024-10-29T12:49:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/upcoming-fda-advisory-panel-for-icecure-s-prosense-r-marketing-authorization-receives 2024-10-29T12:49:00+00:00 weekly 0.7 https://trial.medpath.com/news/protega-pharmaceuticals-receives-fda-approval-for-roxybondtm-oxycodone-morningstar 2024-10-29T12:48:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protega-pharmaceuticals-receives-fda-approval-for-roxybondtm-oxycodone-morningstar 2024-10-29T12:48:44+00:00 weekly 0.7 https://trial.medpath.com/news/pathos-ai-closes-62m-oversubscribed-series-c-round-of-globenewswire 2024-10-29T12:43:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pathos-ai-closes-62m-oversubscribed-series-c-round-of-globenewswire 2024-10-29T12:43:25+00:00 weekly 0.7 https://trial.medpath.com/news/protega-pharmaceuticals-receives-fda-approval-for-roxybondtm-oxycodone-pr-newswire 2024-10-29T12:37:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protega-pharmaceuticals-receives-fda-approval-for-roxybondtm-oxycodone-pr-newswire 2024-10-29T12:37:28+00:00 weekly 0.7 https://trial.medpath.com/news/chiesi-global-rare-diseases-announces-publication-of-results-from-phase-3-bright-biospace 2024-10-29T12:33:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chiesi-global-rare-diseases-announces-publication-of-results-from-phase-3-bright-biospace 2024-10-29T12:33:55+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-in-bioporto-initiates-patient-enrollment-for-us-study-of-pronephro-aki-ngal 2024-10-29T12:33:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-in-bioporto-initiates-patient-enrollment-for-us-study-of-pronephro-aki-ngal 2024-10-29T12:33:54+00:00 weekly 0.7 https://trial.medpath.com/news/mira-pharmaceuticals-ketamir-2-shows-60-greater-efficacy-than-fda-approved-biospace 2024-10-29T12:33:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mira-pharmaceuticals-ketamir-2-shows-60-greater-efficacy-than-fda-approved-biospace 2024-10-29T12:33:54+00:00 weekly 0.7 https://trial.medpath.com/news/shuttle-pharma-completes-clinical-trial-site-enrollment-for-phase-2-of-ropidoxuridine-biospace 2024-10-29T12:33:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shuttle-pharma-completes-clinical-trial-site-enrollment-for-phase-2-of-ropidoxuridine-biospace 2024-10-29T12:33:54+00:00 weekly 0.7 https://trial.medpath.com/news/paragonix-technologies-receives-fda-510-k-clearance-for-kidneyvault-portable-renal 2024-10-29T12:33:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paragonix-technologies-receives-fda-510-k-clearance-for-kidneyvault-portable-renal 2024-10-29T12:33:51+00:00 weekly 0.7 https://trial.medpath.com/news/new-therapy-after-islet-cell-transplant-shows-promise-for-people-with-type-1-diabetes 2024-10-29T12:28:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-therapy-after-islet-cell-transplant-shows-promise-for-people-with-type-1-diabetes 2024-10-29T12:28:41+00:00 weekly 0.7 https://trial.medpath.com/news/eledon-pharmaceuticals-announces-positive-initial-data-from-subjects-with-type-1-diabetes 2024-10-29T12:23:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eledon-pharmaceuticals-announces-positive-initial-data-from-subjects-with-type-1-diabetes 2024-10-29T12:23:37+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-rare-disease-therapy-fasenra-receives-eu-approval 2024-10-29T12:22:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-rare-disease-therapy-fasenra-receives-eu-approval 2024-10-29T12:22:04+00:00 weekly 0.7 https://trial.medpath.com/news/grifols-receives-fda-approval-to-treat-surgical-bleeding-in-globenewswire 2024-10-29T12:21:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grifols-receives-fda-approval-to-treat-surgical-bleeding-in-globenewswire 2024-10-29T12:21:03+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-and-cogstate-strike-strategic-partnership-transforming-clinical-trials-in-morningstar 2024-10-29T12:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medidata-and-cogstate-strike-strategic-partnership-transforming-clinical-trials-in-morningstar 2024-10-29T12:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/spero-therapeutics-gets-investor-suit-over-fda-approval-tossed-bloomberg-law-news 2024-10-29T12:13:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spero-therapeutics-gets-investor-suit-over-fda-approval-tossed-bloomberg-law-news 2024-10-29T12:13:12+00:00 weekly 0.7 https://trial.medpath.com/news/immatics-tcr-t-therapy-shows-good-phase-1-safety-and-survival-data-phase-3-plans-confirmed 2024-10-29T12:11:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immatics-tcr-t-therapy-shows-good-phase-1-safety-and-survival-data-phase-3-plans-confirmed 2024-10-29T12:11:15+00:00 weekly 0.7 https://trial.medpath.com/news/spero-therapeutics-gets-investor-suit-over-fda-approval-tossed-bloomberg-law-news 2024-10-29T12:10:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spero-therapeutics-gets-investor-suit-over-fda-approval-tossed-bloomberg-law-news 2024-10-29T12:10:20+00:00 weekly 0.7 https://trial.medpath.com/news/eledon-pharmaceuticals-announces-positive-initial-data-from-subjects-with-type-1-diabetes 2024-10-29T12:09:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eledon-pharmaceuticals-announces-positive-initial-data-from-subjects-with-type-1-diabetes 2024-10-29T12:09:42+00:00 weekly 0.7 https://trial.medpath.com/news/zai-lab-reports-positive-topline-data-from-phase-3-bridging-trial-evaluating-karxt-for-the 2024-10-29T12:09:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zai-lab-reports-positive-topline-data-from-phase-3-bridging-trial-evaluating-karxt-for-the 2024-10-29T12:09:42+00:00 weekly 0.7 https://trial.medpath.com/news/rallybio-announces-approval-of-clinical-trial-applications-for-phase-2-trial-of-rlyb212-in 2024-10-29T12:08:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rallybio-announces-approval-of-clinical-trial-applications-for-phase-2-trial-of-rlyb212-in 2024-10-29T12:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/rallybio-announces-approval-of-clinical-trial-applications-for-phase-2-trial-of-rlyb212-in 2024-10-29T12:07:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rallybio-announces-approval-of-clinical-trial-applications-for-phase-2-trial-of-rlyb212-in 2024-10-29T12:07:29+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-quarterly-activities-report-q1-fy25-immp-stock-news 2024-10-29T12:07:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-quarterly-activities-report-q1-fy25-immp-stock-news 2024-10-29T12:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/well-health-technologies-corp-and-healwell-ai-inc-expands-strategic-marketscreener 2024-10-29T12:03:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/well-health-technologies-corp-and-healwell-ai-inc-expands-strategic-marketscreener 2024-10-29T12:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/grifols-receives-fda-approval-to-treat-surgical-bleeding-in-pediatric-patients-with-its-fibrin 2024-10-29T12:03:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grifols-receives-fda-approval-to-treat-surgical-bleeding-in-pediatric-patients-with-its-fibrin 2024-10-29T12:03:17+00:00 weekly 0.7 https://trial.medpath.com/news/ehr-data-emerges-as-critical-source-for-real-world-evidence-generation-in-drug-development 2024-10-29T11:56:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ehr-data-emerges-as-critical-source-for-real-world-evidence-generation-in-drug-development 2024-10-29T11:56:51+00:00 weekly 0.7 https://trial.medpath.com/news/briacell-therapeutics-corp-sec-10-k-report-tradingview 2024-10-29T11:56:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/briacell-therapeutics-corp-sec-10-k-report-tradingview 2024-10-29T11:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/resalis-therapeutics-gets-equity-investment-from-sanofi-european-biotechnology 2024-10-29T11:51:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/resalis-therapeutics-gets-equity-investment-from-sanofi-european-biotechnology 2024-10-29T11:51:16+00:00 weekly 0.7 https://trial.medpath.com/news/harmony-biosciences-reports-strong-third-quarter-2024-financial 2024-10-29T11:43:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/harmony-biosciences-reports-strong-third-quarter-2024-financial 2024-10-29T11:43:49+00:00 weekly 0.7 https://trial.medpath.com/news/abeona-therapeutics-r-completes-pz-cel-biologics-license-globenewswire 2024-10-29T11:40:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abeona-therapeutics-r-completes-pz-cel-biologics-license-globenewswire 2024-10-29T11:40:01+00:00 weekly 0.7 https://trial.medpath.com/news/shuttle-pharma-completes-clinical-trial-site-enrollment-for-globenewswire 2024-10-29T11:37:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shuttle-pharma-completes-clinical-trial-site-enrollment-for-globenewswire 2024-10-29T11:37:29+00:00 weekly 0.7 https://trial.medpath.com/news/how-az-s-respiratory-wins-are-ramping-up-for-a-bigger-prize-in-copd-pharmavoice 2024-10-29T11:27:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-az-s-respiratory-wins-are-ramping-up-for-a-bigger-prize-in-copd-pharmavoice 2024-10-29T11:27:52+00:00 weekly 0.7 https://trial.medpath.com/news/shifting-the-ga-paradigm-ophthalmology-times 2024-10-29T11:24:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shifting-the-ga-paradigm-ophthalmology-times 2024-10-29T11:24:06+00:00 weekly 0.7 https://trial.medpath.com/news/invivyd-phase-3-long-term-exploratory-clinical-efficacy-globenewswire 2024-10-29T11:13:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/invivyd-phase-3-long-term-exploratory-clinical-efficacy-globenewswire 2024-10-29T11:13:31+00:00 weekly 0.7 https://trial.medpath.com/news/shorla-oncology-announces-u-s-food-and-drug-administration-fda-expanded-approval 2024-10-29T11:12:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shorla-oncology-announces-u-s-food-and-drug-administration-fda-expanded-approval 2024-10-29T11:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-biosciences-announces-successful-completion-of-end-of-phase-2-interactions-with 2024-10-29T11:10:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sagimet-biosciences-announces-successful-completion-of-end-of-phase-2-interactions-with 2024-10-29T11:10:38+00:00 weekly 0.7 https://trial.medpath.com/news/well-health-and-healwell-ai-expand-strategic-alliance-agreement-to-develop-an-ai 2024-10-29T11:05:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/well-health-and-healwell-ai-expand-strategic-alliance-agreement-to-develop-an-ai 2024-10-29T11:05:32+00:00 weekly 0.7 https://trial.medpath.com/news/kiora-pharmaceuticals-receives-investigational-new-drug-approval-to-initiate-abacus-2-a 2024-10-29T11:04:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kiora-pharmaceuticals-receives-investigational-new-drug-approval-to-initiate-abacus-2-a 2024-10-29T11:04:40+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-and-j-j-face-off-in-crohn-s-disease-with-phase-iii-readouts-at-acg-2024-biospace 2024-10-29T11:01:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-and-j-j-face-off-in-crohn-s-disease-with-phase-iii-readouts-at-acg-2024-biospace 2024-10-29T11:01:18+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-expert-highlights-evolution-of-immunotherapy-in-advanced-hodgkin-lymphoma-treatment 2024-10-29T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-expert-highlights-evolution-of-immunotherapy-in-advanced-hodgkin-lymphoma-treatment 2024-10-29T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kiora-pharmaceuticals-receives-investigational-new-drug-approval-to-initiate-abacus-2-a 2024-10-29T10:59:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kiora-pharmaceuticals-receives-investigational-new-drug-approval-to-initiate-abacus-2-a 2024-10-29T10:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/pentixapharm-holding-ag-us-national-cancer-institute-starts-advanced-clinical-trial-with 2024-10-29T10:52:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pentixapharm-holding-ag-us-national-cancer-institute-starts-advanced-clinical-trial-with 2024-10-29T10:52:18+00:00 weekly 0.7 https://trial.medpath.com/news/dach-region-emerges-as-clinical-trial-hub-despite-eu-s-strict-medical-device-regulations 2024-10-29T10:45:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dach-region-emerges-as-clinical-trial-hub-despite-eu-s-strict-medical-device-regulations 2024-10-29T10:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-2-44-million-private-placement-form-8-k 2024-10-29T10:21:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-2-44-million-private-placement-form-8-k 2024-10-29T10:21:11+00:00 weekly 0.7 https://trial.medpath.com/news/shorla-oncology-announces-u-s-fda-expanded-approval-of-jylamvo-methotrexate-an-oncology-and-autoimmune-drug-for-pediatric-indications 2024-10-29T10:10:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shorla-oncology-announces-u-s-fda-expanded-approval-of-jylamvo-methotrexate-an-oncology-and-autoimmune-drug-for-pediatric-indications 2024-10-29T10:10:59+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-scemblix-granted-fda-accelerated-approval-in-newly-diagnosed-cml 2024-10-29T10:10:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-scemblix-granted-fda-accelerated-approval-in-newly-diagnosed-cml 2024-10-29T10:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/digital-rehabilitation-care-planning-for-people-with-chronic-diseases-rehapro-serve-trials 2024-10-29T09:54:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-rehabilitation-care-planning-for-people-with-chronic-diseases-rehapro-serve-trials 2024-10-29T09:54:13+00:00 weekly 0.7 https://trial.medpath.com/news/niab-scientists-working-on-next-generation-vaccine-against-leptospirosis-the-hindu 2024-10-29T09:51:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/niab-scientists-working-on-next-generation-vaccine-against-leptospirosis-the-hindu 2024-10-29T09:51:56+00:00 weekly 0.7 https://trial.medpath.com/news/devyser-seeks-to-secure-fda-approval-for-ngs-test-for-kidney-transplant-monitoring 2024-10-29T09:26:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/devyser-seeks-to-secure-fda-approval-for-ngs-test-for-kidney-transplant-monitoring 2024-10-29T09:26:43+00:00 weekly 0.7 https://trial.medpath.com/news/linus-health-to-demonstrate-how-digital-health-powers-innovation-at-clinical-trials-on 2024-10-29T09:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/linus-health-to-demonstrate-how-digital-health-powers-innovation-at-clinical-trials-on 2024-10-29T09:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/protega-pharmaceuticals-receives-fda-approval-for-roxybond-oxycodone-hydrochloride-immediate-release-10-mg-tablet-with-abuse-deterrent-technology-for-management-of-pain 2024-10-29T09:10:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protega-pharmaceuticals-receives-fda-approval-for-roxybond-oxycodone-hydrochloride-immediate-release-10-mg-tablet-with-abuse-deterrent-technology-for-management-of-pain 2024-10-29T09:10:29+00:00 weekly 0.7 https://trial.medpath.com/news/linus-health-to-demonstrate-how-digital-health-powers-innovation-at-clinical-trials-on 2024-10-29T09:03:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/linus-health-to-demonstrate-how-digital-health-powers-innovation-at-clinical-trials-on 2024-10-29T09:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/bprw-3-black-medical-schools-receive-funding-to-improve-clinical-trials-press-releases 2024-10-29T09:01:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bprw-3-black-medical-schools-receive-funding-to-improve-clinical-trials-press-releases 2024-10-29T09:01:56+00:00 weekly 0.7 https://trial.medpath.com/news/cinclus-pharma-agrees-with-ema-on-pediatric-study-plan-marketscreener 2024-10-29T08:37:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cinclus-pharma-agrees-with-ema-on-pediatric-study-plan-marketscreener 2024-10-29T08:37:39+00:00 weekly 0.7 https://trial.medpath.com/news/paragonix-s-kidney-vault-receives-fda-nod-for-organ-transport-bioworld 2024-10-29T08:36:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paragonix-s-kidney-vault-receives-fda-nod-for-organ-transport-bioworld 2024-10-29T08:36:10+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-raises-profit-guidance-pushes-off-myelofibrosis-drug-submission-stat-news 2024-10-29T08:29:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-raises-profit-guidance-pushes-off-myelofibrosis-drug-submission-stat-news 2024-10-29T08:29:51+00:00 weekly 0.7 https://trial.medpath.com/news/rvu120-shows-early-promise-in-r-r-metastatic-or-advanced-solid-tumors-onclive 2024-10-29T08:14:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rvu120-shows-early-promise-in-r-r-metastatic-or-advanced-solid-tumors-onclive 2024-10-29T08:14:03+00:00 weekly 0.7 https://trial.medpath.com/news/regeneration-biomedical-presents-data-on-first-cohort-from-globenewswire 2024-10-29T08:13:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneration-biomedical-presents-data-on-first-cohort-from-globenewswire 2024-10-29T08:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/irlab-makes-progress-in-preparation-for-phase-iii-of-mesdopetam-marketscreener 2024-10-29T07:50:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/irlab-makes-progress-in-preparation-for-phase-iii-of-mesdopetam-marketscreener 2024-10-29T07:50:23+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-nanoparticle-albumin-bound-paclitaxel-plus-carboplatin-as-bmc-medicine 2024-10-29T07:39:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-nanoparticle-albumin-bound-paclitaxel-plus-carboplatin-as-bmc-medicine 2024-10-29T07:39:59+00:00 weekly 0.7 https://trial.medpath.com/news/first-children-vaccinated-in-new-clinical-study-seeking-to-expand-the-indication-marketscreener 2024-10-29T07:32:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-children-vaccinated-in-new-clinical-study-seeking-to-expand-the-indication-marketscreener 2024-10-29T07:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/well-health-and-healwell-ai-expand-strategic-alliance-agreement-to-develop-an-ai 2024-10-29T07:29:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/well-health-and-healwell-ai-expand-strategic-alliance-agreement-to-develop-an-ai 2024-10-29T07:29:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-new-drug-application-and-grants-priority-review-for-tlx101-cdx-pixclara 2024-10-29T07:27:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-new-drug-application-and-grants-priority-review-for-tlx101-cdx-pixclara 2024-10-29T07:27:52+00:00 weekly 0.7 https://trial.medpath.com/news/well-health-and-healwell-ai-expand-strategic-alliance-agreement-to-develop-newsfile-corp 2024-10-29T07:25:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/well-health-and-healwell-ai-expand-strategic-alliance-agreement-to-develop-newsfile-corp 2024-10-29T07:25:53+00:00 weekly 0.7 https://trial.medpath.com/news/qiagen-receives-fda-clearance-for-qiastat-dx-mini-panel-to-improve-precision-in-outpatient 2024-10-29T07:16:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qiagen-receives-fda-clearance-for-qiastat-dx-mini-panel-to-improve-precision-in-outpatient 2024-10-29T07:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/cinclus-pharma-agrees-on-pediatric-investigation-plan-pip-with-ema-marketscreener 2024-10-29T06:49:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cinclus-pharma-agrees-on-pediatric-investigation-plan-pip-with-ema-marketscreener 2024-10-29T06:49:53+00:00 weekly 0.7 https://trial.medpath.com/news/irlab-reports-continued-progress-ahead-of-the-mesdopetam-phase-iii-program 2024-10-29T06:40:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/irlab-reports-continued-progress-ahead-of-the-mesdopetam-phase-iii-program 2024-10-29T06:40:41+00:00 weekly 0.7 https://trial.medpath.com/news/cinclus-pharma-agrees-on-pediatric-investigation-plan-pip-with-ema-tradingview 2024-10-29T06:40:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cinclus-pharma-agrees-on-pediatric-investigation-plan-pip-with-ema-tradingview 2024-10-29T06:40:41+00:00 weekly 0.7 https://trial.medpath.com/news/most-hae-patients-attack-free-after-ntla-2002-treatment-in-trial-angioedema-news 2024-10-29T06:40:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/most-hae-patients-attack-free-after-ntla-2002-treatment-in-trial-angioedema-news 2024-10-29T06:40:03+00:00 weekly 0.7 https://trial.medpath.com/news/maze-therapeutics-reports-positive-data-from-phase-i-akd-treatment-trial 2024-10-29T06:36:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maze-therapeutics-reports-positive-data-from-phase-i-akd-treatment-trial 2024-10-29T06:36:38+00:00 weekly 0.7 https://trial.medpath.com/news/first-children-vaccinated-in-new-clinical-study-seeking-to-globenewswire 2024-10-29T06:34:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-children-vaccinated-in-new-clinical-study-seeking-to-globenewswire 2024-10-29T06:34:27+00:00 weekly 0.7 https://trial.medpath.com/news/cinclus-pharma-agrees-on-pediatric-investigation-plan-pip-with-ema-placera 2024-10-29T06:30:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cinclus-pharma-agrees-on-pediatric-investigation-plan-pip-with-ema-placera 2024-10-29T06:30:51+00:00 weekly 0.7 https://trial.medpath.com/news/rezatapopt-monotherapy-remains-under-study-following-discontinuation-of-combination 2024-10-29T06:27:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rezatapopt-monotherapy-remains-under-study-following-discontinuation-of-combination 2024-10-29T06:27:26+00:00 weekly 0.7 https://trial.medpath.com/news/dexmedetomidine-nasal-spray-on-emergence-agitation-after-ear-nose-an-ijgm 2024-10-29T06:25:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dexmedetomidine-nasal-spray-on-emergence-agitation-after-ear-nose-an-ijgm 2024-10-29T06:25:28+00:00 weekly 0.7 https://trial.medpath.com/news/avecho-biotechnology-expands-trials-and-manufacturing-markets-insider 2024-10-29T06:20:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avecho-biotechnology-expands-trials-and-manufacturing-markets-insider 2024-10-29T06:20:56+00:00 weekly 0.7 https://trial.medpath.com/news/shionogi-announces-global-phase-3-trial-demonstrates-post-exposure-prophylactic-use-of 2024-10-29T06:07:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shionogi-announces-global-phase-3-trial-demonstrates-post-exposure-prophylactic-use-of 2024-10-29T06:07:09+00:00 weekly 0.7 https://trial.medpath.com/news/an-electronic-patient-reported-outcome-symptom-monitor-the-chinese-experience-with-rapid 2024-10-29T05:31:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-electronic-patient-reported-outcome-symptom-monitor-the-chinese-experience-with-rapid 2024-10-29T05:31:45+00:00 weekly 0.7 https://trial.medpath.com/news/personalized-medicine-reshapes-breast-cancer-treatment-landscape-expert-highlights-multiple-approaches 2024-10-29T05:00:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/personalized-medicine-reshapes-breast-cancer-treatment-landscape-expert-highlights-multiple-approaches 2024-10-29T05:00:59+00:00 weekly 0.7 https://trial.medpath.com/news/merck-moderna-begin-phase-3-trial-of-mrna-4157-in-combo-with-keytruda-after-pharmabiz 2024-10-29T04:29:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-moderna-begin-phase-3-trial-of-mrna-4157-in-combo-with-keytruda-after-pharmabiz 2024-10-29T04:29:32+00:00 weekly 0.7 https://trial.medpath.com/news/new-cancer-treatment-trial-shrinks-luton-man-s-brain-tumour-by-half-after-just-weeks-of 2024-10-29T04:14:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-cancer-treatment-trial-shrinks-luton-man-s-brain-tumour-by-half-after-just-weeks-of 2024-10-29T04:14:43+00:00 weekly 0.7 https://trial.medpath.com/news/remegen-announces-the-acceptance-of-the-marketing-application-of-telitaccept-for-stock-titan 2024-10-29T04:13:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/remegen-announces-the-acceptance-of-the-marketing-application-of-telitaccept-for-stock-titan 2024-10-29T04:13:07+00:00 weekly 0.7 https://trial.medpath.com/news/dr-reddy-s-launches-bixibat-to-treat-chronic-constipation-in-india-express-pharma 2024-10-29T04:06:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-reddy-s-launches-bixibat-to-treat-chronic-constipation-in-india-express-pharma 2024-10-29T04:06:42+00:00 weekly 0.7 https://trial.medpath.com/news/sheri-yang-and-michael-mitchell-awarded-2-79-million-nih-grant-to-study-new-treatment 2024-10-29T04:03:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sheri-yang-and-michael-mitchell-awarded-2-79-million-nih-grant-to-study-new-treatment 2024-10-29T04:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/mira-pharmaceuticals-ketamir-2-shows-60-greater-efficacy-than-fda-approved 2024-10-29T03:59:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mira-pharmaceuticals-ketamir-2-shows-60-greater-efficacy-than-fda-approved 2024-10-29T03:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/cbp-issues-warning-on-biological-material-import-violations-in-clinical-research 2024-10-29T03:45:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cbp-issues-warning-on-biological-material-import-violations-in-clinical-research 2024-10-29T03:45:08+00:00 weekly 0.7 https://trial.medpath.com/news/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-29T03:43:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-29T03:43:40+00:00 weekly 0.7 https://trial.medpath.com/news/pl-developments-announces-fda-approval-for-omeprazole-otc-anda-and-successful 2024-10-29T03:34:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pl-developments-announces-fda-approval-for-omeprazole-otc-anda-and-successful 2024-10-29T03:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/pl-developments-announces-fda-approval-for-omeprazole-otc-anda-and-successful 2024-10-29T03:19:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pl-developments-announces-fda-approval-for-omeprazole-otc-anda-and-successful 2024-10-29T03:19:23+00:00 weekly 0.7 https://trial.medpath.com/news/pl-developments-announces-fda-approval-for-omeprazole-otc-anda-and-successful 2024-10-29T03:17:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pl-developments-announces-fda-approval-for-omeprazole-otc-anda-and-successful 2024-10-29T03:17:07+00:00 weekly 0.7 https://trial.medpath.com/news/product-launch-modius-sleep-fda-cleared-non-invasive-device-that-treats-pr-newswire 2024-10-29T02:15:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/product-launch-modius-sleep-fda-cleared-non-invasive-device-that-treats-pr-newswire 2024-10-29T02:15:29+00:00 weekly 0.7 https://trial.medpath.com/news/community-based-research-sites-revolutionize-clinical-trial-accessibility-and-diversity 2024-10-29T02:09:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/community-based-research-sites-revolutionize-clinical-trial-accessibility-and-diversity 2024-10-29T02:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/tertiary-lymphoid-structures-linked-to-improved-treatment-outcomes-in-liver-cancer 2024-10-29T01:54:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tertiary-lymphoid-structures-linked-to-improved-treatment-outcomes-in-liver-cancer 2024-10-29T01:54:50+00:00 weekly 0.7 https://trial.medpath.com/news/early-intervention-in-patients-with-asymptomatic-severe-aortic-stenosis-and-myocardial-fibrosis 2024-10-29T01:23:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-intervention-in-patients-with-asymptomatic-severe-aortic-stenosis-and-myocardial-fibrosis 2024-10-29T01:23:21+00:00 weekly 0.7 https://trial.medpath.com/news/acg-2024-j-j-data-reveals-new-crohn-s-treatment-option 2024-10-29T00:57:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acg-2024-j-j-data-reveals-new-crohn-s-treatment-option 2024-10-29T00:57:34+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-brass-hit-with-investor-suit-over-rsv-shot-claims-law360 2024-10-29T00:48:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-brass-hit-with-investor-suit-over-rsv-shot-claims-law360 2024-10-29T00:48:22+00:00 weekly 0.7 https://trial.medpath.com/news/south-korea-s-yuhan-has-690-profit-spike-on-u-s-lung-cancer-drug-sales 2024-10-29T00:35:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/south-korea-s-yuhan-has-690-profit-spike-on-u-s-lung-cancer-drug-sales 2024-10-29T00:35:39+00:00 weekly 0.7 https://trial.medpath.com/news/is-mdma-the-breakthrough-in-treating-post-traumatic-stress-disorder-listnr-articles 2024-10-29T00:10:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-mdma-the-breakthrough-in-treating-post-traumatic-stress-disorder-listnr-articles 2024-10-29T00:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/qol-remains-key-consideration-for-first-line-treatment-of-anemia-in-lower-risk-mds 2024-10-29T00:07:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qol-remains-key-consideration-for-first-line-treatment-of-anemia-in-lower-risk-mds 2024-10-29T00:07:23+00:00 weekly 0.7 https://trial.medpath.com/news/dr-reddy-s-launches-constipation-drug-in-india-the-hindu 2024-10-29T00:01:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-reddy-s-launches-constipation-drug-in-india-the-hindu 2024-10-29T00:01:53+00:00 weekly 0.7 https://trial.medpath.com/news/impella-ecp-confirmed-to-be-safe-for-high-risk-pci-is-fda-approval-next 2024-10-28T23:49:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impella-ecp-confirmed-to-be-safe-for-high-risk-pci-is-fda-approval-next 2024-10-28T23:49:32+00:00 weekly 0.7 https://trial.medpath.com/news/merck-moderna-launch-phase-iii-trial-of-v940-in-combination-with-keytruda-for-resectable 2024-10-28T23:41:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-moderna-launch-phase-iii-trial-of-v940-in-combination-with-keytruda-for-resectable 2024-10-28T23:41:37+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-s-ebglyss-shows-improvement-in-phase-iiib-study-for-atopic-dermatitis 2024-10-28T23:23:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-s-ebglyss-shows-improvement-in-phase-iiib-study-for-atopic-dermatitis 2024-10-28T23:23:49+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-2-44-million-private-placement 2024-10-28T23:16:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-2-44-million-private-placement 2024-10-28T23:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-biosciences-receives-ind-clearance-from-fda-to-proceed-with-phase-2-study-of 2024-10-28T23:14:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tyra-biosciences-receives-ind-clearance-from-fda-to-proceed-with-phase-2-study-of 2024-10-28T23:14:27+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-2-44-million-private-placement-yahoo-finance 2024-10-28T23:12:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-2-44-million-private-placement-yahoo-finance 2024-10-28T23:12:31+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-2-44-million-private-placement-morningstar 2024-10-28T23:10:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-2-44-million-private-placement-morningstar 2024-10-28T23:10:01+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-2-44-million-private-placement-company-markets-data 2024-10-28T23:07:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-2-44-million-private-placement-company-markets-data 2024-10-28T23:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in 2024-10-28T22:54:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in 2024-10-28T22:54:24+00:00 weekly 0.7 https://trial.medpath.com/news/kind-presents-positive-results-of-and017-to-treat-anemia-associated-with-chronic-kidney 2024-10-28T22:07:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kind-presents-positive-results-of-and017-to-treat-anemia-associated-with-chronic-kidney 2024-10-28T22:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/kind-presents-positive-results-of-and017-to-treat-anemia-associated-with-chronic-kidney 2024-10-28T21:44:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kind-presents-positive-results-of-and017-to-treat-anemia-associated-with-chronic-kidney 2024-10-28T21:44:31+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trial-begins-in-mrna-based-therapy-plus-keytruda-in-non-small-cell-lung-cancer 2024-10-28T21:12:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trial-begins-in-mrna-based-therapy-plus-keytruda-in-non-small-cell-lung-cancer 2024-10-28T21:12:02+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-iron-transport-protein-found-in-malaria-parasite-mirage-news 2024-10-28T21:08:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-iron-transport-protein-found-in-malaria-parasite-mirage-news 2024-10-28T21:08:34+00:00 weekly 0.7 https://trial.medpath.com/news/eyepoint-pharmaceuticals-announces-positive-interim-16-week-data-for-ongoing-phase-2 2024-10-28T21:02:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyepoint-pharmaceuticals-announces-positive-interim-16-week-data-for-ongoing-phase-2 2024-10-28T21:02:05+00:00 weekly 0.7